WO2020188015A1 - A dbait molecule in combination with kinase inhibitor for the treatment of cancer - Google Patents
A dbait molecule in combination with kinase inhibitor for the treatment of cancer Download PDFInfo
- Publication number
- WO2020188015A1 WO2020188015A1 PCT/EP2020/057555 EP2020057555W WO2020188015A1 WO 2020188015 A1 WO2020188015 A1 WO 2020188015A1 EP 2020057555 W EP2020057555 W EP 2020057555W WO 2020188015 A1 WO2020188015 A1 WO 2020188015A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- combination
- kinase inhibitor
- pharmaceutical composition
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080019737.1A CN114364798A (en) | 2019-03-21 | 2020-03-19 | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer |
BR112021018168-7A BR112021018168B1 (en) | 2019-03-21 | 2020-03-19 | PHARMACEUTICAL COMPOSITION, COMBINATION AND KIT COMPRISING A DBAIT MOLECULE AND A KINASE INHIBITOR FOR THE TREATMENT OF CANCER |
US17/593,474 US20220143049A1 (en) | 2019-03-21 | 2020-03-19 | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CA3129665A CA3129665A1 (en) | 2019-03-21 | 2020-03-19 | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
JP2021553852A JP2022526713A (en) | 2019-03-21 | 2020-03-19 | Dbait molecule in combination with a kinase inhibitor for the treatment of cancer |
AU2020242287A AU2020242287A1 (en) | 2019-03-21 | 2020-03-19 | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
KR1020217033652A KR20210142154A (en) | 2019-03-21 | 2020-03-19 | DBAIT molecules in combination with kinase inhibitors for the treatment of cancer |
EP20710972.9A EP3942045A1 (en) | 2019-03-21 | 2020-03-19 | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EA202192575A EA202192575A1 (en) | 2019-03-21 | 2020-03-19 | DBAIT COMPOUNDS IN COMBINATION WITH KINASE INHIBITORS FOR CANCER TREATMENT |
MX2021009863A MX2021009863A (en) | 2019-03-21 | 2020-03-19 | A dbait molecule in combination with kinase inhibitor for the treatment of cancer. |
IL284856A IL284856A (en) | 2019-03-21 | 2021-07-14 | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19305349 | 2019-03-21 | ||
EP19305349.3 | 2019-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020188015A1 true WO2020188015A1 (en) | 2020-09-24 |
Family
ID=66103004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2020/057555 WO2020188015A1 (en) | 2019-03-21 | 2020-03-19 | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220143049A1 (en) |
EP (1) | EP3942045A1 (en) |
JP (1) | JP2022526713A (en) |
KR (1) | KR20210142154A (en) |
CN (1) | CN114364798A (en) |
AU (1) | AU2020242287A1 (en) |
BR (1) | BR112021018168B1 (en) |
CA (1) | CA3129665A1 (en) |
EA (1) | EA202192575A1 (en) |
IL (1) | IL284856A (en) |
MX (1) | MX2021009863A (en) |
WO (1) | WO2020188015A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
KR20220165628A (en) * | 2021-06-08 | 2022-12-15 | 한국과학기술원 | Composition for treating or preventing colorectal cancer in combination, comprising SYK inhibitor |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3765613A1 (en) * | 2018-03-13 | 2021-01-20 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
Citations (635)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
WO1999028304A2 (en) | 1997-12-01 | 1999-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pdgf receptor kinase inhibitory compounds, their preparation and compositions |
WO1999054286A2 (en) | 1998-04-17 | 1999-10-28 | Parker Hughes Institute | Btk inhibitors and methods for their identification and use |
WO1999057117A2 (en) | 1998-05-04 | 1999-11-11 | Asta Medica Aktiengesellschaft | Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation |
WO2000042022A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzoheterocycles and their use as mek inhibitors |
WO2000042002A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
WO2000041994A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
WO2000042003A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
WO2000056706A1 (en) | 1999-03-19 | 2000-09-28 | Du Pont Pharmaceuticals Company | Amino-thio-acrylonitriles as mek inhibitors |
WO2000068201A1 (en) | 1999-05-08 | 2000-11-16 | Astrazeneca Ab | Quinoline derivatives as inhibitors of mek enzymes |
WO2000075113A1 (en) | 1999-06-09 | 2000-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
WO2001009134A1 (en) | 1999-07-30 | 2001-02-08 | Novartis Ag | Purine derivatives inhibitors of tyrosine protein kinase syk |
WO2001025238A2 (en) | 1999-10-06 | 2001-04-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
WO2001034574A1 (en) | 1999-11-11 | 2001-05-17 | Osi Pharmaceuticals, Inc. | Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
WO2001047922A2 (en) | 1999-12-24 | 2001-07-05 | Aventis Pharma Limited | Azaindoles |
WO2001052892A2 (en) | 2000-01-24 | 2001-07-26 | Genzyme Corporation | Jak/stat pathway inhibitors and the uses thereof |
WO2001060814A2 (en) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
WO2001064200A2 (en) | 2000-03-03 | 2001-09-07 | Novartis Ag | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
WO2001068619A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
WO2001072711A1 (en) | 2000-03-28 | 2001-10-04 | Wyeth | 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
WO2001072758A1 (en) | 2000-03-28 | 2001-10-04 | Wyeth | Tricyclic protein kinase inhibitors |
WO2001076570A2 (en) | 2000-04-07 | 2001-10-18 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses |
WO2001083485A1 (en) | 2000-04-28 | 2001-11-08 | Bayer Aktiengesellschaft | Imidazopyrimidine derivatives and triazolopyrimidine derivatives |
WO2002069960A2 (en) | 2001-03-06 | 2002-09-12 | Axxima Pharmaceuticals Ag | Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
WO2002092599A1 (en) | 2001-05-14 | 2002-11-21 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives |
WO2003003006A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
WO2003002114A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
WO2003004006A2 (en) | 2001-06-29 | 2003-01-16 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
WO2003027111A1 (en) | 2001-09-27 | 2003-04-03 | Smithkline Beecham Corporation | Chemical compounds |
WO2003035049A2 (en) | 2001-09-20 | 2003-05-01 | Ab Science | Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
WO2003057695A1 (en) | 2001-12-21 | 2003-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 naphthyridines useful as inhibitors of syk kinase |
WO2003063794A2 (en) | 2002-02-01 | 2003-08-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
WO2003077914A1 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2003077892A2 (en) | 2002-03-15 | 2003-09-25 | Novartis Ag | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases |
WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2003101989A1 (en) | 2002-05-30 | 2003-12-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
WO2004005284A1 (en) | 2002-07-09 | 2004-01-15 | Astrazeneca Ab | Substituted 3-cyanoquinolines as mek inhibitors |
WO2004011461A1 (en) | 2002-07-25 | 2004-02-05 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
WO2004014903A1 (en) | 2002-08-02 | 2004-02-19 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
WO2004041814A1 (en) | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
WO2004041789A1 (en) | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
WO2004041810A1 (en) | 2002-11-05 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
WO2004056822A1 (en) | 2002-12-20 | 2004-07-08 | F. Hoffmann-La Roche Ag | Pyridino `2, 3-d! pyrimidine derivatives as selective kdr and fgfr inhibitors |
WO2004058753A1 (en) | 2002-05-06 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase |
WO2004080980A1 (en) | 2003-03-14 | 2004-09-23 | Novartis Ag | 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
WO2004080462A1 (en) | 2003-03-10 | 2004-09-23 | Eisai Co., Ltd. | c-Kit KINASE INHIBITOR |
US20040242582A1 (en) | 2001-04-24 | 2004-12-02 | Green Mark A | Folate mimetics and folate-receptor binding conjugates thereof |
WO2005009389A2 (en) | 2003-07-23 | 2005-02-03 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
WO2005016894A1 (en) | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
WO2005018677A2 (en) | 2003-08-01 | 2005-03-03 | Wyeth Holdings Corporation | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
WO2005021531A1 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-kit inhibitors |
WO2005021537A1 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors |
WO2005021544A2 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine-derivatives as c-kit inhibitors |
WO2005023759A2 (en) | 2003-09-03 | 2005-03-17 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
WO2005023251A1 (en) | 2003-08-29 | 2005-03-17 | Array Biopharma Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2005026158A1 (en) | 2003-09-16 | 2005-03-24 | Novartis Ag | 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors |
WO2005028426A1 (en) | 2003-09-19 | 2005-03-31 | Chugai Seiyaku Kabushiki Kaisha | Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
WO2005027972A2 (en) | 2003-09-23 | 2005-03-31 | Novartis Ag | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
WO2005033316A2 (en) | 2003-09-16 | 2005-04-14 | Basf Aktiengesellschaft | Secretion of proteins from yeasts |
WO2005037836A2 (en) | 2003-10-15 | 2005-04-28 | Osi Pharmaceuticals, Inc. | Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors |
WO2005040378A1 (en) | 2003-10-24 | 2005-05-06 | Institut Curie | Nucleic acids useful for triggering tumor cell lethality |
WO2005049033A1 (en) | 2003-11-17 | 2005-06-02 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases |
WO2005051906A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
WO2005065687A1 (en) | 2004-01-09 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Novel pharmaceutical combinations containing scopine or tropic acid esters and egfr-kinase inhibitors |
WO2005073225A1 (en) | 2004-01-30 | 2005-08-11 | Ab Science | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
WO2005082854A1 (en) | 2004-02-27 | 2005-09-09 | Eisai Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (1) |
WO2005095399A2 (en) | 2004-03-31 | 2005-10-13 | Aventis Pharma S.A. | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors |
WO2005095400A1 (en) | 2004-03-30 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
WO2005097800A1 (en) | 2004-04-02 | 2005-10-20 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
WO2005123696A1 (en) | 2004-06-15 | 2005-12-29 | Astrazeneca Ab | Substituted quinazolones as anti-cancer agents |
WO2006003378A1 (en) | 2004-07-01 | 2006-01-12 | Astrazeneca Ab | Azine-carboxamides as anti-cancer agent |
WO2006011466A1 (en) | 2004-07-26 | 2006-02-02 | Chugai Seiyaku Kabushiki Kaisha | 5-substituted-2-phenylamino-benzamide as mek inhibitor |
WO2006020145A2 (en) | 2004-07-19 | 2006-02-23 | The Johns Hopkins University | Flt3 inhibitors for immune suppression |
WO2006024836A1 (en) | 2004-09-01 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
WO2006024834A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
WO2006034116A1 (en) | 2004-09-17 | 2006-03-30 | Vertex Pharmaceuticals Incorporated | Diaminotriazole compounds useful as protein kinase inhibitors |
WO2006040568A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Quinoxalines as b raf inhibitors |
WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
WO2006056427A1 (en) | 2004-11-24 | 2006-06-01 | Laboratoires Serono S.A. | Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders |
WO2006058752A1 (en) | 2004-12-01 | 2006-06-08 | Laboratoires Serono S.A. | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
WO2006060381A2 (en) | 2004-12-01 | 2006-06-08 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library |
WO2006067446A1 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
WO2006069080A2 (en) | 2004-12-22 | 2006-06-29 | Incyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors |
WO2006080450A1 (en) | 2005-01-27 | 2006-08-03 | Kyowa Hakko Kogyo Co., Ltd. | Igf-1r inhibitor |
WO2006079791A1 (en) | 2005-01-25 | 2006-08-03 | Astrazeneca Ab | Chemical compounds |
WO2006082392A1 (en) | 2005-02-04 | 2006-08-10 | Astrazeneca Ab | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
WO2006087530A1 (en) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
WO2006087538A1 (en) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
WO2006093247A1 (en) | 2005-02-28 | 2006-09-08 | Japan Tobacco Inc. | NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY |
WO2006104161A1 (en) | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-Met AUTOPHOSPHORYLATION INHIBITING POTENCY |
WO2006106437A2 (en) | 2005-04-04 | 2006-10-12 | Ab Science | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors |
WO2006112479A1 (en) | 2005-04-19 | 2006-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Nitrogen-containing heterocyclic compound |
WO2006123113A2 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
WO2006130673A1 (en) | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
WO2006133417A1 (en) | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines as mek inhibitors |
WO2006135719A1 (en) | 2005-06-10 | 2006-12-21 | Janssen Pharmaceutica N.V. | Aminopyrimidines as kinase modulators |
WO2007002258A2 (en) | 2005-06-23 | 2007-01-04 | Merck & Co., Inc. | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met |
WO2007002254A2 (en) | 2005-06-23 | 2007-01-04 | Merck & Co., Inc. | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met |
WO2007004749A1 (en) | 2005-07-05 | 2007-01-11 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
WO2007007919A2 (en) | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
WO2007009681A1 (en) | 2005-07-15 | 2007-01-25 | Glaxo Group Limited | 1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES |
WO2007014011A2 (en) | 2005-07-21 | 2007-02-01 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
WO2007022529A2 (en) | 2005-08-19 | 2007-02-22 | Array Biopharma Inc. | Method of treating inflammatory diseases |
WO2007023768A1 (en) | 2005-08-24 | 2007-03-01 | Eisai R & D Management Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (3) |
WO2007026251A2 (en) | 2005-07-14 | 2007-03-08 | Ab Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
WO2007030680A2 (en) | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
WO2007028445A1 (en) | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
WO2007038669A2 (en) | 2005-09-27 | 2007-04-05 | Irm Llc | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors |
WO2007036630A1 (en) | 2005-09-27 | 2007-04-05 | Aventis Pharma S.A. | Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors |
WO2007040469A2 (en) | 2005-09-15 | 2007-04-12 | Kosak Ken M | Chloroquine coupled compositions and methods for their synthesis |
WO2007042299A1 (en) | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
WO2007044084A2 (en) | 2005-05-18 | 2007-04-19 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
WO2007044515A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
WO2007066185A2 (en) | 2005-12-05 | 2007-06-14 | Pfizer Products Inc. | Polymorphs of a c-met/hgfr inhibitor |
WO2007070514A1 (en) | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
WO2007071963A2 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents |
WO2007071951A1 (en) | 2005-12-21 | 2007-06-28 | Astrazeneca Ab | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
WO2007075554A2 (en) | 2005-12-19 | 2007-07-05 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
WO2007083017A2 (en) | 2006-01-23 | 2007-07-26 | Aventis Pharma S.A. | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
WO2007084557A2 (en) | 2006-01-17 | 2007-07-26 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of janus kinases |
WO2007085540A1 (en) | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
WO2007088345A1 (en) | 2006-01-31 | 2007-08-09 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
WO2007092403A1 (en) | 2006-02-06 | 2007-08-16 | Osi Pharmaceuticals, Inc. | N-phenylbenzotriazolyl c-kit inhibitors |
WO2007111904A2 (en) | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
WO2007113557A1 (en) | 2006-04-05 | 2007-10-11 | Astrazeneca Ab | Substituted quinazolines with anti-cancer activity |
WO2007113558A2 (en) | 2006-04-05 | 2007-10-11 | Astrazeneca Ab | Quinazolinone derivatives having b-raf inhibitory activity |
WO2007117494A1 (en) | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
WO2007119055A1 (en) | 2006-04-18 | 2007-10-25 | Astrazeneca Ab | Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them |
WO2007121279A2 (en) | 2006-04-13 | 2007-10-25 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
WO2007121481A2 (en) | 2006-04-18 | 2007-10-25 | Ardea Biosciences, Inc. | Pyridone sulfonamides and pyridone sulfamides as mek inhibitors |
WO2007124369A2 (en) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Method of inhibiting c kit kinase |
WO2007123269A1 (en) | 2006-04-19 | 2007-11-01 | Astellas Pharma Inc. | Azolecarboxamide derivative |
WO2007123936A1 (en) | 2006-04-19 | 2007-11-01 | Laboratoires Serono Sa | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors |
WO2007129226A2 (en) | 2006-05-09 | 2007-11-15 | New Era Biotech Ltd | Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders |
WO2007136103A1 (en) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
WO2008000922A1 (en) | 2006-01-23 | 2008-01-03 | Aventis Pharma S.A. | Sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
WO2008005877A2 (en) | 2006-06-30 | 2008-01-10 | Board Of Regents, The University Of Texas System | Inhibitors of c-kit and uses thereof |
WO2008008310A2 (en) | 2006-07-10 | 2008-01-17 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2008011080A2 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine |
WO2008016192A2 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
WO2008020203A1 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors |
WO2008022309A2 (en) | 2006-08-18 | 2008-02-21 | F. Hoffmann-La Roche Ag | Polyconjugates for in vivo delivery of polynucleotides |
WO2008023698A1 (en) | 2006-08-23 | 2008-02-28 | Eisai R & D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
WO2008033798A2 (en) | 2006-09-11 | 2008-03-20 | Sanofi-Aventis | A pyrrolopyrazin as syk-kinase inhibitor |
WO2008034866A2 (en) | 2006-09-21 | 2008-03-27 | Institut Curie | Dbait and uses thereof |
WO2008039218A2 (en) | 2006-09-22 | 2008-04-03 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2008045978A1 (en) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
WO2008047831A1 (en) | 2006-10-17 | 2008-04-24 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
WO2008046802A1 (en) | 2006-10-16 | 2008-04-24 | Novartis Ag | Phenylacetamides useful as protein kinase inhibitors |
WO2008068507A2 (en) | 2006-12-08 | 2008-06-12 | Astrazeneca Ab | 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment |
WO2008076143A1 (en) | 2006-12-18 | 2008-06-26 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
WO2008075068A2 (en) | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Acylaminopyrazoles as fgfr inhibitors |
WO2008078091A1 (en) | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
WO2008080134A2 (en) | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
WO2008083354A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors |
WO2008083357A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2008083356A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
WO2008083353A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2008083367A2 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2008084087A2 (en) | 2007-01-12 | 2008-07-17 | Centre National De La Recherche Scientifique | Dbait and its standalone uses thereof |
WO2008089459A1 (en) | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of mek |
WO2008098139A2 (en) | 2007-02-07 | 2008-08-14 | The Regents Of The University Of Colorado | Axl tyrosine kinase inhibitors and methods of making and using the same |
WO2008102870A1 (en) | 2007-02-23 | 2008-08-28 | Eisai R & D Management Co., Ltd. | Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene |
WO2008111441A1 (en) | 2007-03-05 | 2008-09-18 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
WO2008109943A1 (en) | 2007-03-12 | 2008-09-18 | Cytopia Research Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
WO2008116139A2 (en) | 2007-03-22 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | N-heterocyclic compounds useful as inhibitors of janus kinases |
WO2008121742A2 (en) | 2007-03-28 | 2008-10-09 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2008128072A2 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |
WO2008135785A1 (en) | 2007-05-04 | 2008-11-13 | Astrazeneca Ab | 9- (pyrazol- 3 -yl) - 9h- purine-2 -amine and 3- (pyraz0l-3-yl) -3h-imidaz0 [4, 5-b] pyridin-5-amine derivatives and their use for the treatment of cancer |
WO2008157207A2 (en) | 2007-06-13 | 2008-12-24 | Incyte Corporation | Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3- cyclopentylpropanenitrile |
WO2009013462A1 (en) | 2007-07-23 | 2009-01-29 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
WO2009018238A1 (en) | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
WO2009018233A1 (en) | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
WO2009031011A2 (en) | 2007-09-05 | 2009-03-12 | Pfizer Limited | Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
WO2009054468A1 (en) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
WO2009053269A1 (en) | 2007-10-23 | 2009-04-30 | F. Hoffmann-La Roche Ag | Novel kinase inhibitors |
WO2009054864A1 (en) | 2007-10-26 | 2009-04-30 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2009056692A2 (en) | 2007-08-09 | 2009-05-07 | Sanofi-Aventis | Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors |
WO2009062258A1 (en) | 2007-11-15 | 2009-05-22 | Cytopia Research Pty Ltd | N-containing heterocyclic compounds |
WO2009068955A2 (en) | 2007-11-29 | 2009-06-04 | Pfizer Inc. | Polymorphs of a c-met/hgfr inhibitor |
WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
WO2009093049A1 (en) | 2008-01-25 | 2009-07-30 | F. Hoffmann-La Roche Ag | Fused pyridines active as inhibitors of c-met |
WO2009095399A2 (en) | 2008-02-01 | 2009-08-06 | Akinion Pharmaceuticals Ab | Pyrazine derivatives and their use as protein kinase inhbitors |
WO2009098144A1 (en) | 2008-02-05 | 2009-08-13 | F. Hoffmann-La Roche Ag | Novel pyridinones and pyridazinones |
WO2009105712A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
WO2009111278A2 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
WO2009111277A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
WO2009111280A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
WO2009111279A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine raf inhibitors |
WO2009114512A1 (en) | 2008-03-11 | 2009-09-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as jak inhibitors |
WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors |
WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
WO2009127417A1 (en) | 2008-04-16 | 2009-10-22 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline derivatives as axl kinase inhibitors |
WO2009129246A2 (en) | 2008-04-14 | 2009-10-22 | Ardea Biosciences, Inc. | Compositions and methods for preparing and using same |
WO2009131687A2 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2009132202A2 (en) | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
WO2009136995A2 (en) | 2008-04-16 | 2009-11-12 | Portola Pharmaceuticals, Inc. | Inhibitors of syk protein kinase |
WO2009143211A2 (en) | 2008-05-21 | 2009-11-26 | Incyte Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
WO2009143389A1 (en) | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
WO2009145856A1 (en) | 2008-04-16 | 2009-12-03 | Portola Pharmaceuticals, Inc. | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
WO2009155551A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
WO2009153554A1 (en) | 2008-06-19 | 2009-12-23 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
WO2009155565A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
WO2009153592A1 (en) | 2008-06-19 | 2009-12-23 | Astrazeneca Ab | Pyrazole compounds 436 |
WO2009156284A1 (en) | 2008-06-24 | 2009-12-30 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
WO2010005876A2 (en) | 2008-07-09 | 2010-01-14 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2010005879A1 (en) | 2008-07-09 | 2010-01-14 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2010007318A2 (en) | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Novel imidazo[1,2-a]pyrimidine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
WO2010007316A2 (en) | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
WO2010007317A1 (en) | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
WO2010009342A2 (en) | 2008-07-16 | 2010-01-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
WO2010017051A1 (en) | 2008-08-04 | 2010-02-11 | Merck Serono S.A. | Novel phenylamino isonicotinamide compounds |
WO2010019899A1 (en) | 2008-08-14 | 2010-02-18 | Takeda Pharmaceutical Company Limited | cMET INHIBITORS |
WO2010033941A1 (en) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
WO2010048314A1 (en) | 2008-10-22 | 2010-04-29 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
WO2010051549A1 (en) | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
WO2010059668A1 (en) | 2008-11-19 | 2010-05-27 | Vertex Pharmaceuticals Incorporated | A triazolothiadiazole inhibitor of c-met protein kinase |
WO2010068258A1 (en) | 2008-12-08 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Imidazopyrazine syk inhibitors |
WO2010068257A1 (en) | 2008-12-08 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Imidazopyrazine syk inhibitors |
WO2010076764A1 (en) | 2008-12-29 | 2010-07-08 | Universita' Degli Studi Di Parma | Irreversible egfr inhibitor compounds with antiproliferative activity |
WO2010083283A2 (en) | 2009-01-15 | 2010-07-22 | Incyte Corporation | Processes for preparing jak inhibitors and related intermediate compounds |
WO2010083465A1 (en) | 2009-01-16 | 2010-07-22 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
WO2010085597A1 (en) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
WO2010089509A1 (en) | 2009-02-06 | 2010-08-12 | Sanofi-Aventis | Derivatives of 6-(6-substituted-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors |
WO2010089508A1 (en) | 2009-02-06 | 2010-08-12 | Sanofi-Aventis | Derivatives of 6-(6-nh-substituted-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors |
WO2010090764A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
WO2010097248A1 (en) | 2009-01-13 | 2010-09-02 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of syk kinase |
WO2010108652A1 (en) | 2009-03-27 | 2010-09-30 | Ardea Biosciences Inc. | Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors |
WO2010121646A1 (en) | 2009-04-21 | 2010-10-28 | Novartis Ag | Heterocyclic compounds as mek inhibitors |
WO2010126960A1 (en) | 2009-04-29 | 2010-11-04 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
WO2010135621A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
WO2010143664A1 (en) | 2009-06-10 | 2010-12-16 | 中外製薬株式会社 | Tetracyclic compound |
WO2010142752A1 (en) | 2009-06-11 | 2010-12-16 | F. Hoffmann-La Roche Ag | Janus kinase inhibitor compounds and methods |
WO2010147898A2 (en) | 2009-06-15 | 2010-12-23 | Rigel Pharmaceuticals, Inc. | Small molecule inhibitors of spleen tyrosine kinase (syk) |
WO2010145197A1 (en) | 2009-06-15 | 2010-12-23 | Chemizon (Beijing), Ltd. | Novel 6-arylamino pyridone sulfonamides and 6-arylamino pyrazinone sulfonamdies as mek inhibitors |
WO2010149769A1 (en) | 2009-06-26 | 2010-12-29 | Galapagos Nv | 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors |
WO2011003065A2 (en) | 2009-07-02 | 2011-01-06 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
WO2011006074A1 (en) | 2009-07-09 | 2011-01-13 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
WO2011014795A2 (en) | 2009-07-30 | 2011-02-03 | Irm Llc | Compounds and compositions as syk kinase inhibitors |
WO2011014515A1 (en) | 2009-07-30 | 2011-02-03 | Irm Llc | 2, 7 -naphthyridin- 1 -one derivatives as syk kinase inhibitors |
WO2011025951A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
WO2011025965A1 (en) | 2009-08-28 | 2011-03-03 | Genentech, Inc. | Raf inhibitor compounds and methods of use thereof |
WO2011025938A2 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
WO2011025968A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase |
WO2011029046A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Bruton's tyrosine kinase inhibitors |
WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
WO2011039527A1 (en) | 2009-09-30 | 2011-04-07 | Merck Sharp & Dohme Ltd | Formulations for c-met kinase inhibitors |
WO2011047238A1 (en) | 2009-10-16 | 2011-04-21 | Glaxosmithkline Llc | Combination |
WO2011047055A2 (en) | 2009-10-13 | 2011-04-21 | Allostem Therapeutics Llc | Novel mek inhibitors, useful in the treatment of diseases |
WO2011054828A1 (en) | 2009-11-04 | 2011-05-12 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
WO2011075560A1 (en) | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
WO2011075515A1 (en) | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
WO2011079051A1 (en) | 2009-12-23 | 2011-06-30 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
WO2011076419A1 (en) | 2009-12-24 | 2011-06-30 | Almirall, S.A. | Imidazopyridine derivatives as jak inhibitors |
WO2011079142A2 (en) | 2009-12-23 | 2011-06-30 | Arqule, Inc. | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
WO2011086085A1 (en) | 2010-01-12 | 2011-07-21 | Ab Science | Thiazole and oxazole kinase inhibitors |
WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
WO2011092128A1 (en) | 2010-01-29 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and their use as syk kinase inhibitors |
WO2011112995A1 (en) | 2010-03-11 | 2011-09-15 | Gilead Sciences, Inc. | Imidazopyridines syk inhibitors |
WO2011117160A1 (en) | 2010-03-22 | 2011-09-29 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives and their use as jak and syk inhibitors |
WO2011119894A2 (en) | 2010-03-24 | 2011-09-29 | Kinagen, Inc | Heterocyclic compounds useful for kinase inhibition |
WO2011121223A1 (en) | 2010-03-30 | 2011-10-06 | Sanofi-Aventis | 6-(alkyl- or cycloalkyl-triazolopyridazine-sulfanyl) benzothiazole derivatives: preparation, application as medicaments and use as met inhibitors |
WO2011134971A1 (en) | 2010-04-29 | 2011-11-03 | Glaxo Group Limited | 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors |
WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
WO2011143646A1 (en) | 2010-05-14 | 2011-11-17 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
WO2011144585A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors |
WO2011144584A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives as syk and jak inhibitors |
WO2011147764A1 (en) | 2010-05-28 | 2011-12-01 | N.V. Organon | Thieno (2, 3b) pyrazine compounds as b - raf inhibitors |
WO2011149878A1 (en) | 2010-05-27 | 2011-12-01 | Vertex Pharmaceuticals Incorporated | An aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase |
WO2011152351A1 (en) | 2010-05-31 | 2011-12-08 | 小野薬品工業株式会社 | Purinone derivative |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
WO2011161075A1 (en) | 2010-06-22 | 2011-12-29 | Dna Therapeutics | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
WO2012002577A1 (en) | 2010-06-30 | 2012-01-05 | 富士フイルム株式会社 | Novel nicotinamide derivatives or salts thereof |
WO2012005299A1 (en) | 2010-07-07 | 2012-01-12 | 日本新薬株式会社 | Ros tyrosine kinase inhibitor |
WO2012008564A1 (en) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | Nitrogenated aromatic heterocyclic ring derivative |
WO2012008563A1 (en) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | Nitrogenated aromatic heterocyclic ring derivative |
WO2012006960A1 (en) | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
WO2012015677A1 (en) | 2010-07-30 | 2012-02-02 | Eli Lilly And Company | 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5- |
WO2012017239A2 (en) | 2010-08-02 | 2012-02-09 | Astrazeneca Ab | Chemical compounds |
WO2012021444A1 (en) | 2010-08-10 | 2012-02-16 | Avila Therapeutics, Inc. | Besylate salt of a btk inhibitor |
WO2012023597A1 (en) | 2010-08-20 | 2012-02-23 | 中外製薬株式会社 | Composition containing tetracyclic compound |
WO2012025187A2 (en) | 2010-08-27 | 2012-03-01 | Merck Patent Gmbh | Furopyridine derivatives |
WO2012025186A1 (en) | 2010-08-27 | 2012-03-01 | Merck Patent Gmbh | Triazolopyrazine derivatives |
WO2012028332A1 (en) | 2010-08-28 | 2012-03-08 | Lead Discovery Center Gmbh | Pharmaceutically active compounds as axl inhibitors |
WO2012034055A2 (en) | 2010-09-12 | 2012-03-15 | Advenchen Laboratories, Llc | Compounds as c-met kinase inhibitors |
WO2012034091A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors |
WO2012037155A2 (en) | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
WO2012048258A2 (en) | 2010-10-08 | 2012-04-12 | Xcovery Holding Company, Llc | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
WO2012047699A1 (en) | 2010-10-05 | 2012-04-12 | Eli Lilly And Company | Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor |
WO2012061418A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
WO2012059041A1 (en) | 2010-11-02 | 2012-05-10 | Centaurus Biopharma Co., Ltd. | Novel 6-arylamino pyridone carboxamide as mek inhibitors |
WO2012075683A1 (en) | 2010-12-08 | 2012-06-14 | 中国科学院上海药物研究所 | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof |
WO2012095505A1 (en) | 2011-01-12 | 2012-07-19 | Boehringer Ingelheim International Gmbh | Anticancer therapy with dual aurora kinase / mek inhibitors |
WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012123312A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
WO2012123311A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk) |
WO2012135800A1 (en) | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase |
WO2012130780A1 (en) | 2011-03-28 | 2012-10-04 | F. Hoffmann-La Roche Ag | Thiazolopyrimidine compounds |
WO2012135801A1 (en) | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
WO2012137089A1 (en) | 2011-04-05 | 2012-10-11 | Pfizer Limited | Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
WO2012151137A1 (en) | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
WO2012154519A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
WO2012154520A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
WO2012158413A2 (en) | 2011-05-13 | 2012-11-22 | Array Biopharma Inc. | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors |
WO2012163814A1 (en) * | 2011-05-27 | 2012-12-06 | Institut Curie | Cancer treatment by combining dna molecules mimicking double strand breaks with hyperthermia |
WO2012167733A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
WO2012170976A2 (en) | 2011-06-10 | 2012-12-13 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
WO2012167415A1 (en) | 2011-06-10 | 2012-12-13 | 中国科学院广州生物医药与健康研究院 | Pyrimidopyrimidone derivatives, pharmaceutical compositions and uses thereof |
WO2013009582A1 (en) | 2011-07-12 | 2013-01-17 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2013007089A1 (en) | 2011-07-11 | 2013-01-17 | 成都西谷曙光数字技术有限公司 | Simple and precise radio frequency positioning system and method |
WO2013010868A1 (en) | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors |
WO2013010869A1 (en) | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
WO2013010380A1 (en) | 2011-07-19 | 2013-01-24 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2013014170A1 (en) | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
WO2013013308A1 (en) | 2011-07-27 | 2013-01-31 | Beta Pharma Canada Inc. | Spirocyclic molecules as protein kinase inhibitors |
WO2013033070A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS |
WO2013033116A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
WO2013033167A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
WO2013033203A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
WO2013040515A1 (en) | 2011-09-14 | 2013-03-21 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2013047813A1 (en) | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | 1,2,4-triazine-6-carboxamide derivative |
WO2013052391A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2013052394A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
WO2013052393A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2013053983A1 (en) | 2011-10-10 | 2013-04-18 | Orion Corporation | Protein kinase inhibitors |
WO2013059738A2 (en) | 2011-10-19 | 2013-04-25 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
WO2013067274A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity |
WO2013067264A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity |
WO2013067277A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Alkylated piperazine compounds as inhibitors of btk activity |
WO2013064445A1 (en) | 2011-11-01 | 2013-05-10 | F. Hoffmann-La Roche Ag | Imidazopyridazine compounds |
WO2013074633A1 (en) | 2011-11-14 | 2013-05-23 | Cephalon, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
WO2013081016A1 (en) | 2011-11-29 | 2013-06-06 | 小野薬品工業株式会社 | Purinone derivative hydrochloride |
WO2013088257A1 (en) | 2011-12-12 | 2013-06-20 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors |
WO2013091539A1 (en) | 2011-12-21 | 2013-06-27 | 江苏恒瑞医药股份有限公司 | Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof |
WO2013102059A1 (en) | 2011-12-30 | 2013-07-04 | Pharmacyclics, Inc. | Pyrazolo [3, 4-d] pyrimidine and pyrrolo [2, 3-d] pyrimidine compounds as kinase inhibitors |
WO2013099041A1 (en) | 2011-12-28 | 2013-07-04 | 富士フイルム株式会社 | Novel nicotinamide derivative or salt thereof |
WO2013104575A1 (en) | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Thienopyrimidine compounds |
WO2013104573A1 (en) | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Pyridazine amide compounds and their use as syk inhibitors |
WO2013107285A1 (en) | 2012-01-17 | 2013-07-25 | 上海艾力斯医药科技有限公司 | Amino heteroaryl compound, preparation method therefor and use thereof |
WO2013107283A1 (en) | 2012-01-17 | 2013-07-25 | Tianjin Binjiang Pharma, Inc. | Benzoheterocyclic compounds and use thereof |
WO2013109882A1 (en) | 2012-01-20 | 2013-07-25 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
WO2013108809A1 (en) | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | 3,5-disubstituted alkynylbenzene compound and salt thereof |
WO2013116382A1 (en) | 2012-01-31 | 2013-08-08 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
WO2013115280A1 (en) | 2012-01-31 | 2013-08-08 | 第一三共株式会社 | Pyridone derivative |
WO2013124025A1 (en) | 2012-02-21 | 2013-08-29 | Merck Patent Gmbh | Furopyridine derivatives |
WO2013124869A2 (en) | 2012-02-21 | 2013-08-29 | Amrita Vishwa Vidyapeetham University | The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations |
WO2013124026A1 (en) | 2012-02-21 | 2013-08-29 | Merck Patent Gmbh | 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
WO2013126132A1 (en) | 2012-02-21 | 2013-08-29 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
WO2013129369A1 (en) | 2012-02-28 | 2013-09-06 | アステラス製薬株式会社 | Nitrogen-containing aromatic heterocyclic compound |
WO2013136249A1 (en) | 2012-03-14 | 2013-09-19 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
WO2013138495A1 (en) | 2012-03-15 | 2013-09-19 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
WO2013142382A1 (en) | 2012-03-22 | 2013-09-26 | Genosco | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
WO2013148603A1 (en) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives as as btk inhibitors |
WO2013144339A1 (en) | 2012-03-30 | 2013-10-03 | Novartis Ag | Fgfr inhibitor for use in the treatment of hypophosphatemic disorders |
WO2013152135A1 (en) | 2012-04-04 | 2013-10-10 | Dawei Zhang | Substituted quinolines as bruton's tyrosine kinases inhibitors |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
WO2013158859A1 (en) | 2012-04-18 | 2013-10-24 | Cell Signaling Technology, Inc. | Egfr and ros1 in cancer |
WO2013157540A1 (en) | 2012-04-17 | 2013-10-24 | 富士フイルム株式会社 | Nitrogen-containing heterocyclic compound or salt thereof |
WO2013161919A1 (en) | 2012-04-26 | 2013-10-31 | 小野薬品工業株式会社 | Trk-INHIBITING COMPOUND |
WO2013170671A1 (en) | 2012-05-14 | 2013-11-21 | 华东理工大学 | Pteridine ketone derivative and applications thereof as egfr, blk, and flt3 inhibitor |
WO2013176970A1 (en) | 2012-05-22 | 2013-11-28 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2013179033A1 (en) | 2012-05-30 | 2013-12-05 | Astex Therapeutics Limited | Pteridines as fgfr inhibitors |
WO2013180183A1 (en) | 2012-05-30 | 2013-12-05 | 日本新薬株式会社 | Aromatic heterocyclic derivative and pharmaceutical |
WO2013183578A1 (en) | 2012-06-04 | 2013-12-12 | 第一三共株式会社 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR |
WO2013185084A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Pyrimidinyl tyrosine kinase inhibitors |
WO2013188184A1 (en) | 2012-06-14 | 2013-12-19 | Eli Lilly And Company | Inhibitor of jak1 and jak2 |
WO2013192125A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
WO2013192088A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2013192128A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
WO2013192098A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2014000713A1 (en) | 2012-06-29 | 2014-01-03 | Zhejiang Beta Pharma Incorporation | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
WO2014007951A2 (en) | 2012-06-13 | 2014-01-09 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
WO2014005217A1 (en) | 2012-07-06 | 2014-01-09 | Pharmascience Inc. | Protein kinase inhibitors |
WO2014009319A1 (en) | 2012-07-11 | 2014-01-16 | Boehringer Ingelheim International Gmbh | Indolinone derivatives anticancer compounds |
WO2014025976A1 (en) | 2012-08-10 | 2014-02-13 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014023385A1 (en) | 2012-08-07 | 2014-02-13 | Merck Patent Gmbh | Pyridopyrimidine derivatives as protein kinase inhibitors |
WO2014027300A1 (en) | 2012-08-13 | 2014-02-20 | Novartis Ag | Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk) |
WO2014029732A1 (en) | 2012-08-21 | 2014-02-27 | F. Hoffmann-La Roche Ag | Pyrrolo[2,3-b]pyrazines as syk inhibitors |
WO2014031438A2 (en) | 2012-08-20 | 2014-02-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2014032498A1 (en) | 2012-09-03 | 2014-03-06 | Crown Bioscience Inc. (Taicang) | Highly selective c-met inhibitors as anticancer agents |
WO2014039899A1 (en) | 2012-09-10 | 2014-03-13 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
WO2014045029A1 (en) | 2012-09-18 | 2014-03-27 | Ziarco Pharma Ltd | 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors |
WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
WO2014051654A2 (en) | 2012-09-27 | 2014-04-03 | Portola Pharmaceuticals, Inc. | Bicyclic oxa-lactam kinase inhibitors |
WO2014050781A1 (en) | 2012-09-25 | 2014-04-03 | 中外製薬株式会社 | Ret inhibitor |
WO2014055934A2 (en) | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
WO2014055928A2 (en) | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
WO2014060371A1 (en) | 2012-10-19 | 2014-04-24 | F. Hoffmann-La Roche Ag | Inhibitors of syk |
WO2014064134A1 (en) | 2012-10-26 | 2014-05-01 | F. Hoffmann-La Roche Ag | 3,4-disubstituted 1 h-pyrazole and 4,5-disubstituted thiazole inhibitors of syk |
WO2014067417A1 (en) | 2012-11-05 | 2014-05-08 | 沈阳药科大学 | Novel quinoline compound and use thereof |
WO2014068527A1 (en) | 2012-11-02 | 2014-05-08 | Pfizer Inc. | Bruton's tyrosine kinase inhibitors |
WO2014074422A1 (en) | 2012-11-07 | 2014-05-15 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
WO2014078578A1 (en) | 2012-11-15 | 2014-05-22 | Pharmacyclics, Inc. | Pyrrolopyrimidine compounds as kinase inhibitors |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078323A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014082598A1 (en) | 2012-11-30 | 2014-06-05 | Centaurus Biopharma Co., Ltd. | Inhibitors of bruton's tyrosine kinase |
WO2014086032A1 (en) | 2012-12-07 | 2014-06-12 | Hutchison Medipharma Limited | Substituted pyridopyrazines as syk inhibitors |
WO2014093191A1 (en) | 2012-12-12 | 2014-06-19 | Merck Sharp & Dohme Corp. | AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2014100314A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
WO2014105958A2 (en) | 2012-12-26 | 2014-07-03 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
WO2014104757A1 (en) | 2012-12-28 | 2014-07-03 | 크리스탈지노믹스(주) | 2,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including same |
WO2014111037A1 (en) | 2013-01-18 | 2014-07-24 | 上海昀怡健康管理咨询有限公司 | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof |
WO2014116504A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2014114185A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2014113932A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2014123167A1 (en) | 2013-02-08 | 2014-08-14 | 日産化学工業株式会社 | Tricyclic pyrrolopyridine compound, and jak inhibitor |
WO2014129477A1 (en) | 2013-02-20 | 2014-08-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Monocyclic pyridine derivative |
WO2014129431A1 (en) | 2013-02-19 | 2014-08-28 | 小野薬品工業株式会社 | Trk-INHIBITING COMPOUND |
WO2014130693A1 (en) | 2013-02-25 | 2014-08-28 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2014141129A2 (en) | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
WO2014146492A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors |
WO2014152114A1 (en) | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as btk inhibitors |
WO2014151620A1 (en) | 2013-03-14 | 2014-09-25 | Boehringer Ingelheim International Gmbh | 5-thiazolecarboxamide dervatives and their use as btk inhibitors |
WO2014164558A1 (en) | 2013-03-11 | 2014-10-09 | Takeda Pharmaceutical Company Limited | Pyridinyl and fused pyridinyl triazolone derivatives |
WO2014161799A1 (en) | 2013-04-02 | 2014-10-09 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
WO2014162039A1 (en) | 2013-04-04 | 2014-10-09 | Orion Corporation | Protein kinase inhibitors |
WO2014164648A2 (en) | 2013-03-11 | 2014-10-09 | Cephalon, Inc. | Solid state forms of a quinazoline derivative and its use as a braf inhibitor |
WO2014172644A2 (en) | 2013-04-19 | 2014-10-23 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2014176210A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2014176216A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
WO2014180182A1 (en) | 2013-05-10 | 2014-11-13 | 江苏豪森药业股份有限公司 | [1,2,4] triazol [4,3-a] pyridine derivate, preparation method therefor or medical application thereof |
WO2014186706A1 (en) | 2013-05-17 | 2014-11-20 | Incyte Corporation | Bipyrazole derivatives as jak inhibitors |
WO2014187319A1 (en) | 2013-05-21 | 2014-11-27 | Jiangsu Medolution Ltd | Substituted pyrazolopyrimidines as kinases inhibitors |
WO2014193932A1 (en) | 2013-05-29 | 2014-12-04 | Cephalon, Inc. | Pyrrolotriazines as alk inhibitors |
WO2014204263A1 (en) | 2013-06-20 | 2014-12-24 | The Asan Foundation | Substituted pyridinone compounds as mek inhibitors |
WO2014202763A1 (en) | 2013-06-20 | 2014-12-24 | Ab Science | Benzimidazole derivatives as selective proteine kinase inhibitors |
WO2014210255A1 (en) | 2013-06-26 | 2014-12-31 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
WO2014206343A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
WO2015002894A1 (en) | 2013-07-02 | 2015-01-08 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
WO2015012298A1 (en) | 2013-07-24 | 2015-01-29 | 小野薬品工業株式会社 | Quinoline derivative |
WO2015017533A1 (en) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Ntrk2 fusions |
WO2015017502A1 (en) | 2013-07-31 | 2015-02-05 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
WO2015017607A2 (en) | 2013-08-02 | 2015-02-05 | Cephalon, Inc. | METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS |
WO2015017610A1 (en) | 2013-07-31 | 2015-02-05 | Gilead Sciences, Inc. | Syk inhibitors |
WO2015022662A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022926A1 (en) | 2013-08-12 | 2015-02-19 | 大鵬薬品工業株式会社 | Novel fused pyrimidine compound or salt thereof |
WO2015031666A1 (en) | 2013-08-28 | 2015-03-05 | Irm Llc | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
WO2015039334A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015039612A1 (en) | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | Compound inhibiting kinase activities of btk and/or jak3 |
WO2015042085A2 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015048662A2 (en) | 2013-09-30 | 2015-04-02 | X-Rx Discovery, Inc. | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
WO2015048689A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2015056683A1 (en) | 2013-10-16 | 2015-04-23 | 富士フイルム株式会社 | Nitrogen-containing heterocyclic compound salt or crystal thereof, pharmaceutical composition, and flt3 inhibitor |
WO2015061247A2 (en) | 2013-10-21 | 2015-04-30 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
WO2015058589A1 (en) | 2013-10-25 | 2015-04-30 | 上海恒瑞医药有限公司 | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof |
WO2015059668A1 (en) | 2013-10-25 | 2015-04-30 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
WO2015061369A1 (en) | 2013-10-21 | 2015-04-30 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
WO2015068767A1 (en) | 2013-11-08 | 2015-05-14 | 小野薬品工業株式会社 | Pyrrolo pyrimidine derivative |
WO2015081822A1 (en) | 2013-12-02 | 2015-06-11 | 北京键凯科技有限公司 | 3-furyl-2-cyano-2-acrylamide derivative, preparation method therefor, pharmaceutical composition and use thereof |
WO2015084998A1 (en) | 2013-12-05 | 2015-06-11 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2015089139A1 (en) | 2013-12-10 | 2015-06-18 | Genzyme Corporation | Tropomyosin-related kinase (trk) inhibitors |
WO2015095102A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2015095444A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015095099A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015100117A1 (en) | 2013-12-26 | 2015-07-02 | Cephalon, Inc. | Pyrazolo[1,5-a]pyridine derivatives and methods of their use |
WO2015100217A1 (en) | 2013-12-23 | 2015-07-02 | Gilead Sciences, Inc. | Syk inhibitors |
WO2015116485A1 (en) | 2014-01-29 | 2015-08-06 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as btk inhibitors |
WO2015119122A1 (en) | 2014-02-04 | 2015-08-13 | アステラス製薬株式会社 | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient |
WO2015127629A1 (en) | 2014-02-27 | 2015-09-03 | Jiangsu Ascentage Biomed Development Inc. | Indoloquinolone compounds as anaplastic lymphoma kinase (alk) inhibitors |
WO2015132799A2 (en) | 2014-02-03 | 2015-09-11 | Cadila Healthcare Limited | Novel heterocyclic compounds |
WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
WO2015140054A1 (en) | 2014-03-19 | 2015-09-24 | Boehringer Ingelheim International Gmbh | Heteroaryl syk inhibitors |
WO2015143692A1 (en) | 2014-03-28 | 2015-10-01 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as axl inhibitors |
WO2015148350A2 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015144614A1 (en) | 2014-03-24 | 2015-10-01 | Ab Science | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors |
WO2015144801A1 (en) | 2014-03-27 | 2015-10-01 | Janssen Pharmaceutica Nv | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS |
WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015144799A1 (en) | 2014-03-27 | 2015-10-01 | Janssen Pharmaceutica Nv | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS |
WO2015165279A1 (en) | 2014-04-29 | 2015-11-05 | 浙江导明医药科技有限公司 | Polyfluorinated compounds acting as bruton's tyrosine kinase inhibitors |
WO2015169233A1 (en) | 2014-05-07 | 2015-11-12 | 北京赛林泰医药技术有限公司 | Inhibitor of bruton's tyrosine kinase |
WO2015175788A1 (en) | 2014-05-15 | 2015-11-19 | Array Biopharma Inc. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
WO2015174376A1 (en) | 2014-05-14 | 2015-11-19 | 日産化学工業株式会社 | Tricyclic compound and jak inhibitor |
WO2015180685A1 (en) | 2014-05-30 | 2015-12-03 | 北京浦润奥生物科技有限责任公司 | Alk kinase inhibitor, and preparation method and use thereof |
WO2015194764A2 (en) | 2014-06-17 | 2015-12-23 | 한국화학연구원 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
WO2015200341A1 (en) | 2014-06-23 | 2015-12-30 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
WO2016006706A1 (en) | 2014-07-07 | 2016-01-14 | 第一三共株式会社 | Pyridone derivative having tetrahydropyranyl methyl group |
WO2016010809A1 (en) | 2014-07-14 | 2016-01-21 | Gilead Sciences, Inc. | Syk inhibitors |
WO2016019233A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
WO2016021629A1 (en) | 2014-08-06 | 2016-02-11 | 塩野義製薬株式会社 | Heterocyclic and carbocyclic derivative having trka-inhibiting activity |
WO2016027195A1 (en) | 2014-08-21 | 2016-02-25 | Pfizer Inc. | Aminopyrimidinyl compounds as jak inhibitors |
WO2016032209A2 (en) | 2014-08-29 | 2016-03-03 | 양지화학(주) | Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor |
WO2016036796A1 (en) | 2014-09-03 | 2016-03-10 | Genzyme Corporation | Cyclic urea compounds as tropomyosin-related kinase (trk) inhibitors |
WO2016054483A1 (en) | 2014-10-03 | 2016-04-07 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
WO2016050165A1 (en) | 2014-09-30 | 2016-04-07 | 上海海雁医药科技有限公司 | Azabicyclo derivatives, process for preparation thereof and medical use thereof |
WO2016057500A1 (en) | 2014-10-06 | 2016-04-14 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
WO2016054987A1 (en) | 2014-10-11 | 2016-04-14 | 上海翰森生物医药科技有限公司 | Egfr inhibitor, and preparation and application thereof |
WO2016065222A1 (en) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Tricyclic atropisomer compounds |
WO2016066726A2 (en) | 2014-10-30 | 2016-05-06 | Sandoz Ag | Active acrylamides |
WO2016070816A1 (en) | 2014-11-05 | 2016-05-12 | 上海页岩科技有限公司 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof |
WO2016079763A1 (en) | 2014-11-20 | 2016-05-26 | Council Of Scientific & Industrial Research | Novel benzimidazole based egfr inhibitors |
WO2016082713A1 (en) | 2014-11-24 | 2016-06-02 | 中国科学院上海药物研究所 | 2-aminopyrimidine compound and pharmaceutical composition and use thereof |
WO2016091849A2 (en) | 2014-12-11 | 2016-06-16 | Bayer Pharma Aktiengesellschaft | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor |
WO2016097918A1 (en) | 2014-12-18 | 2016-06-23 | Pfizer Inc. | Pyrimidine and triazine derivatives and their use as axl inhibitors |
WO2016104617A1 (en) | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | Quinoline derivative |
WO2016106623A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
WO2016109215A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106652A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Biarylether imidazopyrazine btk inhibitors |
WO2016106626A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
WO2016106624A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106628A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106627A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016112637A1 (en) | 2015-01-14 | 2016-07-21 | 湖北生物医药产业技术研究院有限公司 | Btk inhibitor |
WO2016112847A1 (en) | 2015-01-13 | 2016-07-21 | 北京赛特明强医药科技有限公司 | Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof |
WO2016116900A1 (en) | 2015-01-23 | 2016-07-28 | Gvk Biosciences Private Limited | Inhibitors of trka kinase |
WO2016116025A1 (en) | 2015-01-20 | 2016-07-28 | 南京明德新药研发股份有限公司 | Jak inhibitor |
WO2016123706A1 (en) | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Novel fluorinated derivatives as egfr inhibitors useful for treating cancers |
WO2016125186A1 (en) | 2015-02-03 | 2016-08-11 | Council Of Scientific & Industrial Research | Novel flavone based egfr inhibitors and process for preparation thereof |
WO2016134320A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2016164286A2 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2016161570A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Azacarbazole btk inhibitors |
WO2016161571A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
WO2016166250A1 (en) | 2015-04-14 | 2016-10-20 | Qurient Co., Ltd | Quinoline derivatives as tam rtk inhibitors |
WO2016173484A1 (en) | 2015-04-29 | 2016-11-03 | 南京明德新药研发股份有限公司 | Jak inhibitors |
WO2016191524A1 (en) | 2015-05-28 | 2016-12-01 | Theravance Biopharma R&D Ip, Llc | Naphthyridine compounds as jak kinase inhibitors |
WO2016196840A1 (en) | 2015-06-03 | 2016-12-08 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2016192563A1 (en) | 2015-05-29 | 2016-12-08 | 南京明德新药研发股份有限公司 | Janus kinase inhibitor |
WO2016196776A2 (en) | 2015-06-02 | 2016-12-08 | Pharmacyclics Llc. | Inhibitors of bruton's tyrosine kinase |
WO2016192074A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2017007987A1 (en) | 2015-07-09 | 2017-01-12 | Merck Patent Gmbh | Pyrimidine derivatives as btk inhibitors and uses thereof |
WO2017006953A1 (en) | 2015-07-07 | 2017-01-12 | 塩野義製薬株式会社 | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY |
WO2017006968A1 (en) | 2015-07-07 | 2017-01-12 | 日本たばこ産業株式会社 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
WO2017011776A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2017008761A1 (en) | 2015-07-16 | 2017-01-19 | 正大天晴药业集团股份有限公司 | Aniline pyrimidine derivatives and uses thereof |
WO2017015363A1 (en) | 2015-07-20 | 2017-01-26 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
WO2017013237A1 (en) * | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
WO2017016463A1 (en) | 2015-07-24 | 2017-02-02 | 上海海雁医药科技有限公司 | Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof |
WO2017026718A1 (en) | 2015-08-07 | 2017-02-16 | 한국과학기술연구원 | Novel 3-(isoxazol-3-yl)-pyrazolo[3,4-d]pyrimidin-4-amine compound, which is ret kinase inhibitor |
WO2017028816A1 (en) | 2015-08-20 | 2017-02-23 | 浙江海正药业股份有限公司 | Indole derivative, preparation method thereof, and use thereof in pharmaceutical drug |
WO2017028797A1 (en) | 2015-08-18 | 2017-02-23 | 暨南大学 | Pharmaceutical composition and application replacing quinolone derivative, pharmaceutical acceptable salt, or stereoisomer |
WO2017043550A1 (en) | 2015-09-08 | 2017-03-16 | 大鵬薬品工業株式会社 | Condensed pyrimidine compound or salt thereof |
WO2017046302A1 (en) | 2015-09-18 | 2017-03-23 | Ab Science | Novel oxazole derivatives that inhibit syk |
WO2017046604A1 (en) | 2015-09-16 | 2017-03-23 | Redx Pharma Plc | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer |
WO2017049992A1 (en) | 2015-09-25 | 2017-03-30 | 浙江博生医药有限公司 | Egfr kinase inhibitor and preparation method and use thereof |
WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
WO2017066014A1 (en) | 2015-10-14 | 2017-04-20 | Sunnylife Pharma Inc. | Bruton's tyrosine kinase inhibitors |
WO2017070708A1 (en) | 2015-10-23 | 2017-04-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
WO2017077507A1 (en) | 2015-11-06 | 2017-05-11 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
WO2017079205A1 (en) | 2015-11-03 | 2017-05-11 | Theravance Biopharma R&D Ip, Llc | Jak kinase inhibitor compounds for treatment of respiratory disease |
WO2017076355A1 (en) | 2015-11-05 | 2017-05-11 | 湖北生物医药产业技术研究院有限公司 | Pyrimidine derivative and use thereof |
WO2017087778A1 (en) | 2015-11-19 | 2017-05-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
WO2017091544A1 (en) | 2015-11-24 | 2017-06-01 | Theravance Biopharma R&D Ip, Llc | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
WO2017097224A1 (en) | 2015-12-11 | 2017-06-15 | 四川科伦博泰生物医药股份有限公司 | Azetidine derivative, preparation method therefor, and use thereof |
WO2017106429A2 (en) | 2015-12-16 | 2017-06-22 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as btk inhibitors |
WO2017114383A1 (en) | 2015-12-31 | 2017-07-06 | 合肥中科普瑞昇生物医药科技有限公司 | Novel kinase inhibitor against wild-type egfr and mutated egfr |
WO2017117680A1 (en) | 2016-01-06 | 2017-07-13 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as egfr inhibitors |
WO2017123695A1 (en) | 2016-01-13 | 2017-07-20 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
WO2017121444A1 (en) | 2016-01-11 | 2017-07-20 | Merck Patent Gmbh | Quinolin-2-one derivatives |
WO2017127371A1 (en) | 2016-01-21 | 2017-07-27 | Sunnylife Pharma Inc. | Bruton's tyrosine kinase inhibitors |
WO2017129116A1 (en) | 2016-01-26 | 2017-08-03 | 杭州华东医药集团新药研究院有限公司 | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof |
WO2017128917A1 (en) | 2016-01-29 | 2017-08-03 | 北京诺诚健华医药科技有限公司 | Parazole condensed-ring derivatives and preparation method thereof and application thereof in treatment of cancers, inflammation and immune diseases |
WO2017135399A1 (en) | 2016-02-04 | 2017-08-10 | 塩野義製薬株式会社 | Nitrogen-containing heterocycle having trka inhibitory activity, and carbocyclic derivative |
WO2017140254A1 (en) | 2016-02-19 | 2017-08-24 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof |
WO2017146116A1 (en) | 2016-02-23 | 2017-08-31 | 大鵬薬品工業株式会社 | Novel condensed pyrimidine compound or salt thereof |
WO2017148440A1 (en) | 2016-03-04 | 2017-09-08 | 华东理工大学 | Pteridinone derivative serving as flt3 inhibitor, and uses |
WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
WO2017167182A1 (en) | 2016-04-01 | 2017-10-05 | 合肥中科普瑞昇生物医药科技有限公司 | Selective c-kit kinase inhibitor |
WO2017190048A1 (en) | 2016-04-29 | 2017-11-02 | X-Chem, Inc. | Covalent btk inhibitors and uses thereof |
WO2017205459A1 (en) | 2016-05-26 | 2017-11-30 | Kalyra Pharmaceuticals, Inc. | Egfr inhibitor compounds |
WO2017215630A1 (en) | 2016-06-16 | 2017-12-21 | 正大天晴药业集团股份有限公司 | Pyrrolopyrimidine crystal for preparing jak inhibitor |
WO2018001331A1 (en) | 2016-06-30 | 2018-01-04 | 杭州华东医药集团新药研究院有限公司 | Imidazopyridinamine phenyl derivative and use thereof |
WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
WO2018001251A1 (en) | 2016-06-27 | 2018-01-04 | 杭州雷索药业有限公司 | Benzofuran pyrazole amine protein kinase inhibitor |
WO2018009017A1 (en) | 2016-07-07 | 2018-01-11 | Daewoong Pharmaceutical Co., Ltd. | NOVEL 4-AMINOPYRAZOLO[3,4-d]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
WO2018010514A1 (en) | 2016-07-13 | 2018-01-18 | 南京天印健华医药科技有限公司 | Heterocyclic compound used as fgfr inhibitor |
WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
WO2018028438A1 (en) | 2016-08-09 | 2018-02-15 | 南京天印健华医药科技有限公司 | Heterocyclic compound as fgfr inhibitor |
WO2018035080A1 (en) | 2016-08-16 | 2018-02-22 | Merck Patent Gmbh | 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof |
WO2018044767A2 (en) | 2016-08-29 | 2018-03-08 | The Regents Of The University Of Michigan | Aminopyrimidines as alk inhibitors |
WO2018053190A1 (en) | 2016-09-14 | 2018-03-22 | Gilead Sciences, Inc. | Syk inhibitors |
WO2018049781A1 (en) | 2016-09-19 | 2018-03-22 | 北京天诚医药科技有限公司 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof |
WO2018053189A2 (en) | 2016-09-14 | 2018-03-22 | Gilead Sciences, Inc. | Syk inhibitors |
WO2018050052A1 (en) | 2016-09-19 | 2018-03-22 | 郑州泰基鸿诺医药股份有限公司 | Compound containing pyrimidine ring, egfr inhibitor and application thereof |
WO2018060714A1 (en) | 2016-09-29 | 2018-04-05 | Daiichi Sankyo Company, Limited | Pyridine compound |
WO2018071454A1 (en) | 2016-10-10 | 2018-04-19 | Andrews Steven W | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2018071447A1 (en) | 2016-10-10 | 2018-04-19 | Andrews Steven W | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2018079759A1 (en) | 2016-10-31 | 2018-05-03 | 塩野義製薬株式会社 | Fused heterocycle having trka inhibitory activity and fused carbocycle derivative |
WO2018088780A1 (en) | 2016-11-08 | 2018-05-17 | Daewoong Pharmaceutical Co., Ltd. | Novel pyrrolopyrimidine derivatives and pharmaceutical composition comprising the same |
WO2018090792A1 (en) | 2016-11-15 | 2018-05-24 | 杭州和正医药有限公司 | Selective bruton's tyrosine kinase inhibitor and use thereof |
WO2018094134A1 (en) | 2016-11-18 | 2018-05-24 | The Regents Of The University Of Michigan | 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-ones as alk inhibitors |
WO2018095398A1 (en) | 2016-11-24 | 2018-05-31 | 中国科学院上海药物研究所 | Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method and use thereof |
WO2018108083A1 (en) | 2016-12-12 | 2018-06-21 | 杭州英创医药科技有限公司 | Heterocyclic compound as syk inhibitor and/or syk-hdac dual inhibitor |
WO2018112140A1 (en) | 2016-12-15 | 2018-06-21 | Ariad Pharmaceuticals, Inc. | Benzimidazole compounds as c-kit inhibitors |
WO2018108064A1 (en) | 2016-12-13 | 2018-06-21 | 南京明德新药研发股份有限公司 | Spiro-aryl-phosphorus-oxygen compound as fourth generation of egfr kinase inhibitor |
WO2018112136A1 (en) | 2016-12-15 | 2018-06-21 | Ariad Pharmaceuticals, Inc. | Aminothiazole compounds as c-kit inhibitors |
WO2018121228A1 (en) | 2016-12-28 | 2018-07-05 | 中国科学院上海药物研究所 | Compound having axl inhibitory activity, preparation method therefor and use thereof |
WO2018121650A1 (en) | 2016-12-29 | 2018-07-05 | 南京明德新药研发股份有限公司 | Fgfr inhibitor |
WO2018121758A1 (en) | 2016-12-30 | 2018-07-05 | 南京明德新药研发股份有限公司 | Quinazoline compound for egfr inhibition |
WO2018127184A1 (en) | 2017-01-06 | 2018-07-12 | 北京赛林泰医药技术有限公司 | Anaplastic lymphoma kinase inhibitor and preparation method and use thereof |
WO2018129645A1 (en) | 2017-01-10 | 2018-07-19 | Wang, Wei | Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
WO2018133151A1 (en) | 2017-01-20 | 2018-07-26 | 成都倍特药业有限公司 | Compound used as bruton's tyrosine kinase inhibitor and preparation method and application thereof |
WO2018145525A1 (en) | 2017-02-08 | 2018-08-16 | 中国医药研究开发中心有限公司 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof |
WO2018153293A1 (en) | 2017-02-27 | 2018-08-30 | 北京赛特明强医药科技有限公司 | Dioxanoquinazoline, dioxanoquinazoline-type compound, preparation method therefor and use thereof |
WO2018153373A1 (en) | 2017-02-27 | 2018-08-30 | 贝达药业股份有限公司 | Fgfr inhibitor and application thereof |
WO2018154131A1 (en) | 2017-02-27 | 2018-08-30 | Merck Patent Gmbh | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone |
WO2018170381A1 (en) | 2017-03-16 | 2018-09-20 | Andrews Steven W | Macrocyclic compounds as ros1 kinase inhibitors |
WO2018175512A1 (en) | 2017-03-22 | 2018-09-27 | Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. | Bruton's tyrosine kinase inhibitors |
WO2018187355A1 (en) | 2017-04-03 | 2018-10-11 | Health Research Inc. | Met kinase inhibitors and uses therefor |
WO2018192532A1 (en) | 2017-04-19 | 2018-10-25 | 华东理工大学 | Heterocyclic compound as btk inhibitor and application thereof |
WO2018192536A1 (en) | 2017-04-19 | 2018-10-25 | 华东理工大学 | Pyrimido-heterocyclic compound serving as bruton tyrosine kinase inhibitor and applications thereof |
WO2018196757A1 (en) | 2017-04-25 | 2018-11-01 | 中国药科大学 | 4-aminopyrimidine compound, and preparation method therefor and application thereof |
WO2018199166A1 (en) | 2017-04-27 | 2018-11-01 | 持田製薬株式会社 | Novel tetrahydronaphthyl urea derivatives |
WO2018204238A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Fused imidazo-piperidine jak inhibitor compound |
WO2018208132A1 (en) | 2017-05-12 | 2018-11-15 | Korea Research Institute Of Chemical Technology | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient |
WO2018215389A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
WO2018215390A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
WO2018218963A1 (en) | 2017-06-02 | 2018-12-06 | 无锡双良生物科技有限公司 | Pharmaceutically acceptable salt of egfr inhibitor, crystal form thereof, preparation method therefor and application thereof |
WO2018228475A1 (en) | 2017-06-14 | 2018-12-20 | 正大天晴药业集团股份有限公司 | Syk inhibitor and use method therefor |
WO2018233655A1 (en) | 2017-06-22 | 2018-12-27 | 上海度德医药科技有限公司 | Heteroaryl compound having pharmaceutical activity |
WO2019001419A1 (en) | 2017-06-27 | 2019-01-03 | Janssen Pharmaceutica Nv | New quinolinone compounds |
WO2019010295A1 (en) | 2017-07-05 | 2019-01-10 | Cs Pharmatech Limited | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
WO2019034076A1 (en) | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr inhibitor and medical application thereof |
WO2019034538A1 (en) | 2017-08-18 | 2019-02-21 | Universität Regensburg | Synthesis, pharmacology and use of new and selective fms-like tyrosine kinase 3 (flt3) flt3 inhibitors |
WO2019034128A1 (en) | 2017-08-18 | 2019-02-21 | 浙江海正药业股份有限公司 | Pyrrolotriazine derivative, preparation method and use thereof |
WO2019034153A1 (en) | 2017-08-18 | 2019-02-21 | 北京韩美药品有限公司 | Chemical compound, pharmaceutical composition thereof, and use and application thereof |
WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY |
WO2019034075A1 (en) | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr and egfr inhibitor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10072298B2 (en) * | 2013-04-17 | 2018-09-11 | Life Technologies Corporation | Gene fusions and gene variants associated with cancer |
EP3423068A1 (en) * | 2016-03-01 | 2019-01-09 | Onxeo | Treatment of cancer by systemic administration of dbait molecules |
-
2020
- 2020-03-19 AU AU2020242287A patent/AU2020242287A1/en active Pending
- 2020-03-19 EA EA202192575A patent/EA202192575A1/en unknown
- 2020-03-19 EP EP20710972.9A patent/EP3942045A1/en active Pending
- 2020-03-19 KR KR1020217033652A patent/KR20210142154A/en unknown
- 2020-03-19 JP JP2021553852A patent/JP2022526713A/en active Pending
- 2020-03-19 US US17/593,474 patent/US20220143049A1/en active Pending
- 2020-03-19 BR BR112021018168-7A patent/BR112021018168B1/en active IP Right Grant
- 2020-03-19 WO PCT/EP2020/057555 patent/WO2020188015A1/en active Application Filing
- 2020-03-19 CA CA3129665A patent/CA3129665A1/en active Pending
- 2020-03-19 MX MX2021009863A patent/MX2021009863A/en unknown
- 2020-03-19 CN CN202080019737.1A patent/CN114364798A/en active Pending
-
2021
- 2021-07-14 IL IL284856A patent/IL284856A/en unknown
Patent Citations (654)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
WO1999028304A2 (en) | 1997-12-01 | 1999-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pdgf receptor kinase inhibitory compounds, their preparation and compositions |
WO1999054286A2 (en) | 1998-04-17 | 1999-10-28 | Parker Hughes Institute | Btk inhibitors and methods for their identification and use |
WO1999057117A2 (en) | 1998-05-04 | 1999-11-11 | Asta Medica Aktiengesellschaft | Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation |
WO2000042022A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzoheterocycles and their use as mek inhibitors |
WO2000042002A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
WO2000041994A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
WO2000042003A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
WO2000056706A1 (en) | 1999-03-19 | 2000-09-28 | Du Pont Pharmaceuticals Company | Amino-thio-acrylonitriles as mek inhibitors |
WO2000068201A1 (en) | 1999-05-08 | 2000-11-16 | Astrazeneca Ab | Quinoline derivatives as inhibitors of mek enzymes |
WO2000075113A1 (en) | 1999-06-09 | 2000-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
WO2001009134A1 (en) | 1999-07-30 | 2001-02-08 | Novartis Ag | Purine derivatives inhibitors of tyrosine protein kinase syk |
WO2001025238A2 (en) | 1999-10-06 | 2001-04-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
WO2001034574A1 (en) | 1999-11-11 | 2001-05-17 | Osi Pharmaceuticals, Inc. | Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
WO2001047922A2 (en) | 1999-12-24 | 2001-07-05 | Aventis Pharma Limited | Azaindoles |
WO2001052892A2 (en) | 2000-01-24 | 2001-07-26 | Genzyme Corporation | Jak/stat pathway inhibitors and the uses thereof |
WO2001060814A2 (en) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
WO2001064200A2 (en) | 2000-03-03 | 2001-09-07 | Novartis Ag | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
WO2001068619A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
WO2001072711A1 (en) | 2000-03-28 | 2001-10-04 | Wyeth | 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
WO2001072758A1 (en) | 2000-03-28 | 2001-10-04 | Wyeth | Tricyclic protein kinase inhibitors |
WO2001076570A2 (en) | 2000-04-07 | 2001-10-18 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses |
WO2001083485A1 (en) | 2000-04-28 | 2001-11-08 | Bayer Aktiengesellschaft | Imidazopyrimidine derivatives and triazolopyrimidine derivatives |
WO2002069960A2 (en) | 2001-03-06 | 2002-09-12 | Axxima Pharmaceuticals Ag | Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
US20040242582A1 (en) | 2001-04-24 | 2004-12-02 | Green Mark A | Folate mimetics and folate-receptor binding conjugates thereof |
WO2002092599A1 (en) | 2001-05-14 | 2002-11-21 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives |
WO2003003006A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
WO2003002114A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
WO2003004006A2 (en) | 2001-06-29 | 2003-01-16 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
WO2003035049A2 (en) | 2001-09-20 | 2003-05-01 | Ab Science | Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
WO2003027111A1 (en) | 2001-09-27 | 2003-04-03 | Smithkline Beecham Corporation | Chemical compounds |
WO2003057695A1 (en) | 2001-12-21 | 2003-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 naphthyridines useful as inhibitors of syk kinase |
WO2003063794A2 (en) | 2002-02-01 | 2003-08-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
WO2003077914A1 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2003077892A2 (en) | 2002-03-15 | 2003-09-25 | Novartis Ag | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases |
WO2004058753A1 (en) | 2002-05-06 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase |
WO2003101989A1 (en) | 2002-05-30 | 2003-12-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
WO2004005284A1 (en) | 2002-07-09 | 2004-01-15 | Astrazeneca Ab | Substituted 3-cyanoquinolines as mek inhibitors |
WO2004011461A1 (en) | 2002-07-25 | 2004-02-05 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
WO2004014903A1 (en) | 2002-08-02 | 2004-02-19 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
WO2004041789A1 (en) | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
WO2004041814A1 (en) | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
WO2004041810A1 (en) | 2002-11-05 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
WO2004056822A1 (en) | 2002-12-20 | 2004-07-08 | F. Hoffmann-La Roche Ag | Pyridino `2, 3-d! pyrimidine derivatives as selective kdr and fgfr inhibitors |
WO2004080462A1 (en) | 2003-03-10 | 2004-09-23 | Eisai Co., Ltd. | c-Kit KINASE INHIBITOR |
WO2004080980A1 (en) | 2003-03-14 | 2004-09-23 | Novartis Ag | 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
WO2005009389A2 (en) | 2003-07-23 | 2005-02-03 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
WO2005018677A2 (en) | 2003-08-01 | 2005-03-03 | Wyeth Holdings Corporation | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
WO2005016894A1 (en) | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
WO2005021531A1 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-kit inhibitors |
WO2005021537A1 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors |
WO2005021544A2 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine-derivatives as c-kit inhibitors |
WO2005023251A1 (en) | 2003-08-29 | 2005-03-17 | Array Biopharma Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2005023759A2 (en) | 2003-09-03 | 2005-03-17 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
WO2005026158A1 (en) | 2003-09-16 | 2005-03-24 | Novartis Ag | 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors |
WO2005033316A2 (en) | 2003-09-16 | 2005-04-14 | Basf Aktiengesellschaft | Secretion of proteins from yeasts |
WO2005028426A1 (en) | 2003-09-19 | 2005-03-31 | Chugai Seiyaku Kabushiki Kaisha | Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
WO2005027972A2 (en) | 2003-09-23 | 2005-03-31 | Novartis Ag | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
WO2005037836A2 (en) | 2003-10-15 | 2005-04-28 | Osi Pharmaceuticals, Inc. | Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors |
WO2005040378A1 (en) | 2003-10-24 | 2005-05-06 | Institut Curie | Nucleic acids useful for triggering tumor cell lethality |
WO2005049033A1 (en) | 2003-11-17 | 2005-06-02 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases |
WO2005051906A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
WO2005051300A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
WO2005051301A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
WO2005051302A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
WO2005065687A1 (en) | 2004-01-09 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Novel pharmaceutical combinations containing scopine or tropic acid esters and egfr-kinase inhibitors |
WO2005073225A1 (en) | 2004-01-30 | 2005-08-11 | Ab Science | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
WO2005082854A1 (en) | 2004-02-27 | 2005-09-09 | Eisai Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (1) |
WO2005082855A1 (en) | 2004-02-27 | 2005-09-09 | Eisai Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (2) |
WO2005095400A1 (en) | 2004-03-30 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
WO2005095399A2 (en) | 2004-03-31 | 2005-10-13 | Aventis Pharma S.A. | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors |
WO2005097800A1 (en) | 2004-04-02 | 2005-10-20 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
WO2005123696A1 (en) | 2004-06-15 | 2005-12-29 | Astrazeneca Ab | Substituted quinazolones as anti-cancer agents |
WO2006003378A1 (en) | 2004-07-01 | 2006-01-12 | Astrazeneca Ab | Azine-carboxamides as anti-cancer agent |
WO2006020145A2 (en) | 2004-07-19 | 2006-02-23 | The Johns Hopkins University | Flt3 inhibitors for immune suppression |
WO2006011466A1 (en) | 2004-07-26 | 2006-02-02 | Chugai Seiyaku Kabushiki Kaisha | 5-substituted-2-phenylamino-benzamide as mek inhibitor |
WO2006024834A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
WO2006024836A1 (en) | 2004-09-01 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
WO2006034116A1 (en) | 2004-09-17 | 2006-03-30 | Vertex Pharmaceuticals Incorporated | Diaminotriazole compounds useful as protein kinase inhibitors |
WO2006040568A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Quinoxalines as b raf inhibitors |
WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
WO2006056427A1 (en) | 2004-11-24 | 2006-06-01 | Laboratoires Serono S.A. | Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders |
WO2006058752A1 (en) | 2004-12-01 | 2006-06-08 | Laboratoires Serono S.A. | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
WO2006060381A2 (en) | 2004-12-01 | 2006-06-08 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library |
WO2006067446A1 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
WO2006069080A2 (en) | 2004-12-22 | 2006-06-29 | Incyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors |
WO2006079791A1 (en) | 2005-01-25 | 2006-08-03 | Astrazeneca Ab | Chemical compounds |
WO2006080450A1 (en) | 2005-01-27 | 2006-08-03 | Kyowa Hakko Kogyo Co., Ltd. | Igf-1r inhibitor |
WO2006082392A1 (en) | 2005-02-04 | 2006-08-10 | Astrazeneca Ab | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
WO2006087530A1 (en) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
WO2006087538A1 (en) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
WO2006093247A1 (en) | 2005-02-28 | 2006-09-08 | Japan Tobacco Inc. | NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY |
WO2006104161A1 (en) | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-Met AUTOPHOSPHORYLATION INHIBITING POTENCY |
WO2006106437A2 (en) | 2005-04-04 | 2006-10-12 | Ab Science | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors |
WO2006112479A1 (en) | 2005-04-19 | 2006-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Nitrogen-containing heterocyclic compound |
WO2006123113A2 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
WO2007044084A2 (en) | 2005-05-18 | 2007-04-19 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
WO2006130673A1 (en) | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
WO2006133417A1 (en) | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines as mek inhibitors |
WO2006135719A1 (en) | 2005-06-10 | 2006-12-21 | Janssen Pharmaceutica N.V. | Aminopyrimidines as kinase modulators |
WO2007002258A2 (en) | 2005-06-23 | 2007-01-04 | Merck & Co., Inc. | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met |
WO2007002254A2 (en) | 2005-06-23 | 2007-01-04 | Merck & Co., Inc. | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met |
WO2007004749A1 (en) | 2005-07-05 | 2007-01-11 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
WO2007007919A2 (en) | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
WO2007026251A2 (en) | 2005-07-14 | 2007-03-08 | Ab Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
WO2007009681A1 (en) | 2005-07-15 | 2007-01-25 | Glaxo Group Limited | 1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES |
WO2007028445A1 (en) | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
WO2007014011A2 (en) | 2005-07-21 | 2007-02-01 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
WO2007022529A2 (en) | 2005-08-19 | 2007-02-22 | Array Biopharma Inc. | Method of treating inflammatory diseases |
WO2007023768A1 (en) | 2005-08-24 | 2007-03-01 | Eisai R & D Management Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (3) |
WO2007030680A2 (en) | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
WO2007040469A2 (en) | 2005-09-15 | 2007-04-12 | Kosak Ken M | Chloroquine coupled compositions and methods for their synthesis |
WO2007038669A2 (en) | 2005-09-27 | 2007-04-05 | Irm Llc | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors |
WO2007036630A1 (en) | 2005-09-27 | 2007-04-05 | Aventis Pharma S.A. | Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors |
WO2007044515A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
WO2007042299A1 (en) | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
WO2007042298A1 (en) | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
WO2007066185A2 (en) | 2005-12-05 | 2007-06-14 | Pfizer Products Inc. | Polymorphs of a c-met/hgfr inhibitor |
WO2007070514A1 (en) | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
WO2007075554A2 (en) | 2005-12-19 | 2007-07-05 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
WO2007071951A1 (en) | 2005-12-21 | 2007-06-28 | Astrazeneca Ab | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
WO2007071963A2 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents |
WO2007084557A2 (en) | 2006-01-17 | 2007-07-26 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of janus kinases |
WO2007083017A2 (en) | 2006-01-23 | 2007-07-26 | Aventis Pharma S.A. | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
WO2008000922A1 (en) | 2006-01-23 | 2008-01-03 | Aventis Pharma S.A. | Sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
WO2007085540A1 (en) | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
WO2007088345A1 (en) | 2006-01-31 | 2007-08-09 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
WO2007092403A1 (en) | 2006-02-06 | 2007-08-16 | Osi Pharmaceuticals, Inc. | N-phenylbenzotriazolyl c-kit inhibitors |
WO2007111904A2 (en) | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
WO2007113558A2 (en) | 2006-04-05 | 2007-10-11 | Astrazeneca Ab | Quinazolinone derivatives having b-raf inhibitory activity |
WO2007117494A1 (en) | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
WO2007113557A1 (en) | 2006-04-05 | 2007-10-11 | Astrazeneca Ab | Substituted quinazolines with anti-cancer activity |
WO2007121279A2 (en) | 2006-04-13 | 2007-10-25 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
WO2007121481A2 (en) | 2006-04-18 | 2007-10-25 | Ardea Biosciences, Inc. | Pyridone sulfonamides and pyridone sulfamides as mek inhibitors |
WO2007119055A1 (en) | 2006-04-18 | 2007-10-25 | Astrazeneca Ab | Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them |
WO2007123269A1 (en) | 2006-04-19 | 2007-11-01 | Astellas Pharma Inc. | Azolecarboxamide derivative |
WO2007123936A1 (en) | 2006-04-19 | 2007-11-01 | Laboratoires Serono Sa | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors |
WO2007124369A2 (en) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Method of inhibiting c kit kinase |
WO2007129226A2 (en) | 2006-05-09 | 2007-11-15 | New Era Biotech Ltd | Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders |
WO2007136103A1 (en) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
WO2008005877A2 (en) | 2006-06-30 | 2008-01-10 | Board Of Regents, The University Of Texas System | Inhibitors of c-kit and uses thereof |
WO2008008310A2 (en) | 2006-07-10 | 2008-01-17 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2008011080A2 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine |
WO2008016192A2 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
WO2008020203A1 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors |
WO2008022309A2 (en) | 2006-08-18 | 2008-02-21 | F. Hoffmann-La Roche Ag | Polyconjugates for in vivo delivery of polynucleotides |
WO2008023698A1 (en) | 2006-08-23 | 2008-02-28 | Eisai R & D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
WO2008033798A2 (en) | 2006-09-11 | 2008-03-20 | Sanofi-Aventis | A pyrrolopyrazin as syk-kinase inhibitor |
WO2008034866A2 (en) | 2006-09-21 | 2008-03-27 | Institut Curie | Dbait and uses thereof |
WO2008039218A2 (en) | 2006-09-22 | 2008-04-03 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2008045978A1 (en) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
WO2008046802A1 (en) | 2006-10-16 | 2008-04-24 | Novartis Ag | Phenylacetamides useful as protein kinase inhibitors |
WO2008047831A1 (en) | 2006-10-17 | 2008-04-24 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
WO2008068507A2 (en) | 2006-12-08 | 2008-06-12 | Astrazeneca Ab | 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment |
WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
WO2008076143A1 (en) | 2006-12-18 | 2008-06-26 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
WO2008075068A2 (en) | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Acylaminopyrazoles as fgfr inhibitors |
WO2008078091A1 (en) | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
WO2008080134A2 (en) | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
WO2008083356A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
WO2008083357A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2008083354A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors |
WO2008083353A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2008083367A2 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2008084087A2 (en) | 2007-01-12 | 2008-07-17 | Centre National De La Recherche Scientifique | Dbait and its standalone uses thereof |
WO2008089459A1 (en) | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of mek |
WO2008098139A2 (en) | 2007-02-07 | 2008-08-14 | The Regents Of The University Of Colorado | Axl tyrosine kinase inhibitors and methods of making and using the same |
WO2008102870A1 (en) | 2007-02-23 | 2008-08-28 | Eisai R & D Management Co., Ltd. | Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene |
WO2008111441A1 (en) | 2007-03-05 | 2008-09-18 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
WO2008109943A1 (en) | 2007-03-12 | 2008-09-18 | Cytopia Research Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
WO2008116139A2 (en) | 2007-03-22 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | N-heterocyclic compounds useful as inhibitors of janus kinases |
WO2008121742A2 (en) | 2007-03-28 | 2008-10-09 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2008128072A2 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |
WO2008135785A1 (en) | 2007-05-04 | 2008-11-13 | Astrazeneca Ab | 9- (pyrazol- 3 -yl) - 9h- purine-2 -amine and 3- (pyraz0l-3-yl) -3h-imidaz0 [4, 5-b] pyridin-5-amine derivatives and their use for the treatment of cancer |
WO2008157207A2 (en) | 2007-06-13 | 2008-12-24 | Incyte Corporation | Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3- cyclopentylpropanenitrile |
WO2009013462A1 (en) | 2007-07-23 | 2009-01-29 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
WO2009018238A1 (en) | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
WO2009018233A1 (en) | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
WO2009056692A2 (en) | 2007-08-09 | 2009-05-07 | Sanofi-Aventis | Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors |
WO2009031011A2 (en) | 2007-09-05 | 2009-03-12 | Pfizer Limited | Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
WO2009053269A1 (en) | 2007-10-23 | 2009-04-30 | F. Hoffmann-La Roche Ag | Novel kinase inhibitors |
WO2009054468A1 (en) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
WO2009054864A1 (en) | 2007-10-26 | 2009-04-30 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2009062258A1 (en) | 2007-11-15 | 2009-05-22 | Cytopia Research Pty Ltd | N-containing heterocyclic compounds |
WO2009068955A2 (en) | 2007-11-29 | 2009-06-04 | Pfizer Inc. | Polymorphs of a c-met/hgfr inhibitor |
WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
WO2009093049A1 (en) | 2008-01-25 | 2009-07-30 | F. Hoffmann-La Roche Ag | Fused pyridines active as inhibitors of c-met |
WO2009095399A2 (en) | 2008-02-01 | 2009-08-06 | Akinion Pharmaceuticals Ab | Pyrazine derivatives and their use as protein kinase inhbitors |
WO2009098144A1 (en) | 2008-02-05 | 2009-08-13 | F. Hoffmann-La Roche Ag | Novel pyridinones and pyridazinones |
WO2009105712A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
WO2009111277A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
WO2009111278A2 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
WO2009111280A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
WO2009111279A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine raf inhibitors |
WO2009114512A1 (en) | 2008-03-11 | 2009-09-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as jak inhibitors |
WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors |
WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
WO2009129246A2 (en) | 2008-04-14 | 2009-10-22 | Ardea Biosciences, Inc. | Compositions and methods for preparing and using same |
WO2009127417A1 (en) | 2008-04-16 | 2009-10-22 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline derivatives as axl kinase inhibitors |
WO2009136995A2 (en) | 2008-04-16 | 2009-11-12 | Portola Pharmaceuticals, Inc. | Inhibitors of syk protein kinase |
WO2009145856A1 (en) | 2008-04-16 | 2009-12-03 | Portola Pharmaceuticals, Inc. | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
WO2009131687A2 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2009132202A2 (en) | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
WO2009143389A1 (en) | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
WO2009143211A2 (en) | 2008-05-21 | 2009-11-26 | Incyte Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
WO2009153554A1 (en) | 2008-06-19 | 2009-12-23 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
WO2009153592A1 (en) | 2008-06-19 | 2009-12-23 | Astrazeneca Ab | Pyrazole compounds 436 |
WO2009155551A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
WO2009155565A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
WO2009156284A1 (en) | 2008-06-24 | 2009-12-30 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
WO2010005876A2 (en) | 2008-07-09 | 2010-01-14 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2010005879A1 (en) | 2008-07-09 | 2010-01-14 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2010009342A2 (en) | 2008-07-16 | 2010-01-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
WO2010007318A2 (en) | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Novel imidazo[1,2-a]pyrimidine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
WO2010007317A1 (en) | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
WO2010007316A2 (en) | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
WO2010017051A1 (en) | 2008-08-04 | 2010-02-11 | Merck Serono S.A. | Novel phenylamino isonicotinamide compounds |
WO2010019899A1 (en) | 2008-08-14 | 2010-02-18 | Takeda Pharmaceutical Company Limited | cMET INHIBITORS |
WO2010033941A1 (en) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
WO2010048314A1 (en) | 2008-10-22 | 2010-04-29 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
WO2010051549A1 (en) | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
WO2010059668A1 (en) | 2008-11-19 | 2010-05-27 | Vertex Pharmaceuticals Incorporated | A triazolothiadiazole inhibitor of c-met protein kinase |
WO2010068257A1 (en) | 2008-12-08 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Imidazopyrazine syk inhibitors |
WO2010068258A1 (en) | 2008-12-08 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Imidazopyrazine syk inhibitors |
WO2010076764A1 (en) | 2008-12-29 | 2010-07-08 | Universita' Degli Studi Di Parma | Irreversible egfr inhibitor compounds with antiproliferative activity |
WO2010097248A1 (en) | 2009-01-13 | 2010-09-02 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of syk kinase |
WO2010083283A2 (en) | 2009-01-15 | 2010-07-22 | Incyte Corporation | Processes for preparing jak inhibitors and related intermediate compounds |
WO2010083465A1 (en) | 2009-01-16 | 2010-07-22 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
WO2010085597A1 (en) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
WO2010089509A1 (en) | 2009-02-06 | 2010-08-12 | Sanofi-Aventis | Derivatives of 6-(6-substituted-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors |
WO2010089508A1 (en) | 2009-02-06 | 2010-08-12 | Sanofi-Aventis | Derivatives of 6-(6-nh-substituted-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors |
WO2010090764A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
WO2010108652A1 (en) | 2009-03-27 | 2010-09-30 | Ardea Biosciences Inc. | Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors |
WO2010121646A1 (en) | 2009-04-21 | 2010-10-28 | Novartis Ag | Heterocyclic compounds as mek inhibitors |
WO2010126960A1 (en) | 2009-04-29 | 2010-11-04 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
WO2010135621A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
WO2010143664A1 (en) | 2009-06-10 | 2010-12-16 | 中外製薬株式会社 | Tetracyclic compound |
WO2010142752A1 (en) | 2009-06-11 | 2010-12-16 | F. Hoffmann-La Roche Ag | Janus kinase inhibitor compounds and methods |
WO2010147898A2 (en) | 2009-06-15 | 2010-12-23 | Rigel Pharmaceuticals, Inc. | Small molecule inhibitors of spleen tyrosine kinase (syk) |
WO2010145197A1 (en) | 2009-06-15 | 2010-12-23 | Chemizon (Beijing), Ltd. | Novel 6-arylamino pyridone sulfonamides and 6-arylamino pyrazinone sulfonamdies as mek inhibitors |
WO2010149769A1 (en) | 2009-06-26 | 2010-12-29 | Galapagos Nv | 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors |
WO2011003065A2 (en) | 2009-07-02 | 2011-01-06 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
WO2011006074A1 (en) | 2009-07-09 | 2011-01-13 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
WO2011014795A2 (en) | 2009-07-30 | 2011-02-03 | Irm Llc | Compounds and compositions as syk kinase inhibitors |
WO2011014515A1 (en) | 2009-07-30 | 2011-02-03 | Irm Llc | 2, 7 -naphthyridin- 1 -one derivatives as syk kinase inhibitors |
WO2011025951A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
WO2011025965A1 (en) | 2009-08-28 | 2011-03-03 | Genentech, Inc. | Raf inhibitor compounds and methods of use thereof |
WO2011025938A2 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
WO2011025968A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase |
WO2011029046A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Bruton's tyrosine kinase inhibitors |
WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
WO2011039527A1 (en) | 2009-09-30 | 2011-04-07 | Merck Sharp & Dohme Ltd | Formulations for c-met kinase inhibitors |
WO2011047055A2 (en) | 2009-10-13 | 2011-04-21 | Allostem Therapeutics Llc | Novel mek inhibitors, useful in the treatment of diseases |
WO2011047238A1 (en) | 2009-10-16 | 2011-04-21 | Glaxosmithkline Llc | Combination |
WO2011054828A1 (en) | 2009-11-04 | 2011-05-12 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
WO2011075560A1 (en) | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
WO2011075515A1 (en) | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
WO2011079142A2 (en) | 2009-12-23 | 2011-06-30 | Arqule, Inc. | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
WO2011079051A1 (en) | 2009-12-23 | 2011-06-30 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
WO2011076419A1 (en) | 2009-12-24 | 2011-06-30 | Almirall, S.A. | Imidazopyridine derivatives as jak inhibitors |
WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
WO2011086085A1 (en) | 2010-01-12 | 2011-07-21 | Ab Science | Thiazole and oxazole kinase inhibitors |
WO2011092128A1 (en) | 2010-01-29 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and their use as syk kinase inhibitors |
WO2011112995A1 (en) | 2010-03-11 | 2011-09-15 | Gilead Sciences, Inc. | Imidazopyridines syk inhibitors |
WO2011117160A1 (en) | 2010-03-22 | 2011-09-29 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives and their use as jak and syk inhibitors |
WO2011119894A2 (en) | 2010-03-24 | 2011-09-29 | Kinagen, Inc | Heterocyclic compounds useful for kinase inhibition |
WO2011121223A1 (en) | 2010-03-30 | 2011-10-06 | Sanofi-Aventis | 6-(alkyl- or cycloalkyl-triazolopyridazine-sulfanyl) benzothiazole derivatives: preparation, application as medicaments and use as met inhibitors |
WO2011134971A1 (en) | 2010-04-29 | 2011-11-03 | Glaxo Group Limited | 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors |
WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
WO2011143646A1 (en) | 2010-05-14 | 2011-11-17 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
WO2011144585A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors |
WO2011144584A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives as syk and jak inhibitors |
WO2011149878A1 (en) | 2010-05-27 | 2011-12-01 | Vertex Pharmaceuticals Incorporated | An aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase |
WO2011147764A1 (en) | 2010-05-28 | 2011-12-01 | N.V. Organon | Thieno (2, 3b) pyrazine compounds as b - raf inhibitors |
WO2011152351A1 (en) | 2010-05-31 | 2011-12-08 | 小野薬品工業株式会社 | Purinone derivative |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
WO2011161075A1 (en) | 2010-06-22 | 2011-12-29 | Dna Therapeutics | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
WO2012002577A1 (en) | 2010-06-30 | 2012-01-05 | 富士フイルム株式会社 | Novel nicotinamide derivatives or salts thereof |
WO2012005299A1 (en) | 2010-07-07 | 2012-01-12 | 日本新薬株式会社 | Ros tyrosine kinase inhibitor |
WO2012006960A1 (en) | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
WO2012008563A1 (en) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | Nitrogenated aromatic heterocyclic ring derivative |
WO2012008564A1 (en) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | Nitrogenated aromatic heterocyclic ring derivative |
WO2012015677A1 (en) | 2010-07-30 | 2012-02-02 | Eli Lilly And Company | 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5- |
WO2012017239A2 (en) | 2010-08-02 | 2012-02-09 | Astrazeneca Ab | Chemical compounds |
WO2012021444A1 (en) | 2010-08-10 | 2012-02-16 | Avila Therapeutics, Inc. | Besylate salt of a btk inhibitor |
WO2012023597A1 (en) | 2010-08-20 | 2012-02-23 | 中外製薬株式会社 | Composition containing tetracyclic compound |
WO2012025187A2 (en) | 2010-08-27 | 2012-03-01 | Merck Patent Gmbh | Furopyridine derivatives |
WO2012025186A1 (en) | 2010-08-27 | 2012-03-01 | Merck Patent Gmbh | Triazolopyrazine derivatives |
WO2012028332A1 (en) | 2010-08-28 | 2012-03-08 | Lead Discovery Center Gmbh | Pharmaceutically active compounds as axl inhibitors |
WO2012034091A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors |
WO2012034055A2 (en) | 2010-09-12 | 2012-03-15 | Advenchen Laboratories, Llc | Compounds as c-met kinase inhibitors |
WO2012037155A2 (en) | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
WO2012047699A1 (en) | 2010-10-05 | 2012-04-12 | Eli Lilly And Company | Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor |
WO2012048258A2 (en) | 2010-10-08 | 2012-04-12 | Xcovery Holding Company, Llc | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
WO2012061418A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
WO2012059041A1 (en) | 2010-11-02 | 2012-05-10 | Centaurus Biopharma Co., Ltd. | Novel 6-arylamino pyridone carboxamide as mek inhibitors |
WO2012075683A1 (en) | 2010-12-08 | 2012-06-14 | 中国科学院上海药物研究所 | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof |
WO2012095505A1 (en) | 2011-01-12 | 2012-07-19 | Boehringer Ingelheim International Gmbh | Anticancer therapy with dual aurora kinase / mek inhibitors |
WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012123312A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
WO2012123311A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk) |
WO2012130780A1 (en) | 2011-03-28 | 2012-10-04 | F. Hoffmann-La Roche Ag | Thiazolopyrimidine compounds |
WO2012135800A1 (en) | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase |
WO2012135801A1 (en) | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
WO2012137089A1 (en) | 2011-04-05 | 2012-10-11 | Pfizer Limited | Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
WO2012151137A1 (en) | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
WO2012154519A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
WO2012154520A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
WO2012158413A2 (en) | 2011-05-13 | 2012-11-22 | Array Biopharma Inc. | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors |
WO2012163814A1 (en) * | 2011-05-27 | 2012-12-06 | Institut Curie | Cancer treatment by combining dna molecules mimicking double strand breaks with hyperthermia |
WO2012167733A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
WO2012170976A2 (en) | 2011-06-10 | 2012-12-13 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
WO2012167415A1 (en) | 2011-06-10 | 2012-12-13 | 中国科学院广州生物医药与健康研究院 | Pyrimidopyrimidone derivatives, pharmaceutical compositions and uses thereof |
WO2013007089A1 (en) | 2011-07-11 | 2013-01-17 | 成都西谷曙光数字技术有限公司 | Simple and precise radio frequency positioning system and method |
WO2013009582A1 (en) | 2011-07-12 | 2013-01-17 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2013010868A1 (en) | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors |
WO2013010869A1 (en) | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
WO2013010380A1 (en) | 2011-07-19 | 2013-01-24 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2013014170A1 (en) | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
WO2013013308A1 (en) | 2011-07-27 | 2013-01-31 | Beta Pharma Canada Inc. | Spirocyclic molecules as protein kinase inhibitors |
WO2013033116A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
WO2013033070A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS |
WO2013033167A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
WO2013033203A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
WO2013040515A1 (en) | 2011-09-14 | 2013-03-21 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2013047813A1 (en) | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | 1,2,4-triazine-6-carboxamide derivative |
WO2013052391A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2013052394A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
WO2013052393A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2013053983A1 (en) | 2011-10-10 | 2013-04-18 | Orion Corporation | Protein kinase inhibitors |
WO2013059738A2 (en) | 2011-10-19 | 2013-04-25 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
WO2013064445A1 (en) | 2011-11-01 | 2013-05-10 | F. Hoffmann-La Roche Ag | Imidazopyridazine compounds |
WO2013067274A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity |
WO2013067264A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity |
WO2013067277A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Alkylated piperazine compounds as inhibitors of btk activity |
WO2013074633A1 (en) | 2011-11-14 | 2013-05-23 | Cephalon, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
WO2013081016A1 (en) | 2011-11-29 | 2013-06-06 | 小野薬品工業株式会社 | Purinone derivative hydrochloride |
WO2013088257A1 (en) | 2011-12-12 | 2013-06-20 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors |
WO2013088256A1 (en) | 2011-12-12 | 2013-06-20 | Dr. Reddy's Laboratories Ltd. | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors |
WO2013091539A1 (en) | 2011-12-21 | 2013-06-27 | 江苏恒瑞医药股份有限公司 | Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof |
WO2013099041A1 (en) | 2011-12-28 | 2013-07-04 | 富士フイルム株式会社 | Novel nicotinamide derivative or salt thereof |
WO2013102059A1 (en) | 2011-12-30 | 2013-07-04 | Pharmacyclics, Inc. | Pyrazolo [3, 4-d] pyrimidine and pyrrolo [2, 3-d] pyrimidine compounds as kinase inhibitors |
WO2013104575A1 (en) | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Thienopyrimidine compounds |
WO2013104573A1 (en) | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Pyridazine amide compounds and their use as syk inhibitors |
WO2013107285A1 (en) | 2012-01-17 | 2013-07-25 | 上海艾力斯医药科技有限公司 | Amino heteroaryl compound, preparation method therefor and use thereof |
WO2013107283A1 (en) | 2012-01-17 | 2013-07-25 | Tianjin Binjiang Pharma, Inc. | Benzoheterocyclic compounds and use thereof |
WO2013108809A1 (en) | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | 3,5-disubstituted alkynylbenzene compound and salt thereof |
WO2013109882A1 (en) | 2012-01-20 | 2013-07-25 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
WO2013116382A1 (en) | 2012-01-31 | 2013-08-08 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
WO2013115280A1 (en) | 2012-01-31 | 2013-08-08 | 第一三共株式会社 | Pyridone derivative |
WO2013124025A1 (en) | 2012-02-21 | 2013-08-29 | Merck Patent Gmbh | Furopyridine derivatives |
WO2013124869A2 (en) | 2012-02-21 | 2013-08-29 | Amrita Vishwa Vidyapeetham University | The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations |
WO2013124026A1 (en) | 2012-02-21 | 2013-08-29 | Merck Patent Gmbh | 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
WO2013126132A1 (en) | 2012-02-21 | 2013-08-29 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
WO2013129369A1 (en) | 2012-02-28 | 2013-09-06 | アステラス製薬株式会社 | Nitrogen-containing aromatic heterocyclic compound |
WO2013136249A1 (en) | 2012-03-14 | 2013-09-19 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
WO2013136254A1 (en) | 2012-03-14 | 2013-09-19 | Lupin Limited | Heterocyclyl compounds |
WO2013138495A1 (en) | 2012-03-15 | 2013-09-19 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
WO2013142382A1 (en) | 2012-03-22 | 2013-09-26 | Genosco | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
WO2013148603A1 (en) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives as as btk inhibitors |
WO2013144339A1 (en) | 2012-03-30 | 2013-10-03 | Novartis Ag | Fgfr inhibitor for use in the treatment of hypophosphatemic disorders |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
WO2013152135A1 (en) | 2012-04-04 | 2013-10-10 | Dawei Zhang | Substituted quinolines as bruton's tyrosine kinases inhibitors |
WO2013157540A1 (en) | 2012-04-17 | 2013-10-24 | 富士フイルム株式会社 | Nitrogen-containing heterocyclic compound or salt thereof |
WO2013158859A1 (en) | 2012-04-18 | 2013-10-24 | Cell Signaling Technology, Inc. | Egfr and ros1 in cancer |
WO2013161919A1 (en) | 2012-04-26 | 2013-10-31 | 小野薬品工業株式会社 | Trk-INHIBITING COMPOUND |
WO2013170671A1 (en) | 2012-05-14 | 2013-11-21 | 华东理工大学 | Pteridine ketone derivative and applications thereof as egfr, blk, and flt3 inhibitor |
WO2013176970A1 (en) | 2012-05-22 | 2013-11-28 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2013179033A1 (en) | 2012-05-30 | 2013-12-05 | Astex Therapeutics Limited | Pteridines as fgfr inhibitors |
WO2013180183A1 (en) | 2012-05-30 | 2013-12-05 | 日本新薬株式会社 | Aromatic heterocyclic derivative and pharmaceutical |
WO2013183578A1 (en) | 2012-06-04 | 2013-12-12 | 第一三共株式会社 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR |
WO2013185084A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Pyrimidinyl tyrosine kinase inhibitors |
WO2014007951A2 (en) | 2012-06-13 | 2014-01-09 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
WO2013188184A1 (en) | 2012-06-14 | 2013-12-19 | Eli Lilly And Company | Inhibitor of jak1 and jak2 |
WO2013192125A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
WO2013192128A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
WO2013192088A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2013192098A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2014000713A1 (en) | 2012-06-29 | 2014-01-03 | Zhejiang Beta Pharma Incorporation | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
WO2014005217A1 (en) | 2012-07-06 | 2014-01-09 | Pharmascience Inc. | Protein kinase inhibitors |
WO2014009319A1 (en) | 2012-07-11 | 2014-01-16 | Boehringer Ingelheim International Gmbh | Indolinone derivatives anticancer compounds |
WO2014023385A1 (en) | 2012-08-07 | 2014-02-13 | Merck Patent Gmbh | Pyridopyrimidine derivatives as protein kinase inhibitors |
WO2014025976A1 (en) | 2012-08-10 | 2014-02-13 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014027300A1 (en) | 2012-08-13 | 2014-02-20 | Novartis Ag | Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk) |
WO2014031438A2 (en) | 2012-08-20 | 2014-02-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2014029732A1 (en) | 2012-08-21 | 2014-02-27 | F. Hoffmann-La Roche Ag | Pyrrolo[2,3-b]pyrazines as syk inhibitors |
WO2014032498A1 (en) | 2012-09-03 | 2014-03-06 | Crown Bioscience Inc. (Taicang) | Highly selective c-met inhibitors as anticancer agents |
WO2014039899A1 (en) | 2012-09-10 | 2014-03-13 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
WO2014045029A1 (en) | 2012-09-18 | 2014-03-27 | Ziarco Pharma Ltd | 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors |
WO2014050781A1 (en) | 2012-09-25 | 2014-04-03 | 中外製薬株式会社 | Ret inhibitor |
WO2014051654A2 (en) | 2012-09-27 | 2014-04-03 | Portola Pharmaceuticals, Inc. | Bicyclic oxa-lactam kinase inhibitors |
WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
WO2014055934A2 (en) | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
WO2014055928A2 (en) | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
WO2014060371A1 (en) | 2012-10-19 | 2014-04-24 | F. Hoffmann-La Roche Ag | Inhibitors of syk |
WO2014064134A1 (en) | 2012-10-26 | 2014-05-01 | F. Hoffmann-La Roche Ag | 3,4-disubstituted 1 h-pyrazole and 4,5-disubstituted thiazole inhibitors of syk |
WO2014068527A1 (en) | 2012-11-02 | 2014-05-08 | Pfizer Inc. | Bruton's tyrosine kinase inhibitors |
WO2014067417A1 (en) | 2012-11-05 | 2014-05-08 | 沈阳药科大学 | Novel quinoline compound and use thereof |
WO2014074422A1 (en) | 2012-11-07 | 2014-05-15 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078323A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078578A1 (en) | 2012-11-15 | 2014-05-22 | Pharmacyclics, Inc. | Pyrrolopyrimidine compounds as kinase inhibitors |
WO2014082598A1 (en) | 2012-11-30 | 2014-06-05 | Centaurus Biopharma Co., Ltd. | Inhibitors of bruton's tyrosine kinase |
WO2014086032A1 (en) | 2012-12-07 | 2014-06-12 | Hutchison Medipharma Limited | Substituted pyridopyrazines as syk inhibitors |
WO2014093191A1 (en) | 2012-12-12 | 2014-06-19 | Merck Sharp & Dohme Corp. | AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2014100314A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
WO2014105958A2 (en) | 2012-12-26 | 2014-07-03 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
WO2014104757A1 (en) | 2012-12-28 | 2014-07-03 | 크리스탈지노믹스(주) | 2,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including same |
WO2014111037A1 (en) | 2013-01-18 | 2014-07-24 | 上海昀怡健康管理咨询有限公司 | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof |
WO2014113932A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2014114185A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2014116504A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2014123167A1 (en) | 2013-02-08 | 2014-08-14 | 日産化学工業株式会社 | Tricyclic pyrrolopyridine compound, and jak inhibitor |
WO2014129431A1 (en) | 2013-02-19 | 2014-08-28 | 小野薬品工業株式会社 | Trk-INHIBITING COMPOUND |
WO2014129477A1 (en) | 2013-02-20 | 2014-08-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Monocyclic pyridine derivative |
WO2014130693A1 (en) | 2013-02-25 | 2014-08-28 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2014164648A2 (en) | 2013-03-11 | 2014-10-09 | Cephalon, Inc. | Solid state forms of a quinazoline derivative and its use as a braf inhibitor |
WO2014164558A1 (en) | 2013-03-11 | 2014-10-09 | Takeda Pharmaceutical Company Limited | Pyridinyl and fused pyridinyl triazolone derivatives |
WO2014151620A1 (en) | 2013-03-14 | 2014-09-25 | Boehringer Ingelheim International Gmbh | 5-thiazolecarboxamide dervatives and their use as btk inhibitors |
WO2014141129A2 (en) | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
WO2014152114A1 (en) | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as btk inhibitors |
WO2014146492A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors |
WO2014161799A1 (en) | 2013-04-02 | 2014-10-09 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
WO2014162039A1 (en) | 2013-04-04 | 2014-10-09 | Orion Corporation | Protein kinase inhibitors |
WO2014172644A2 (en) | 2013-04-19 | 2014-10-23 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2014176210A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2014176216A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
WO2014180182A1 (en) | 2013-05-10 | 2014-11-13 | 江苏豪森药业股份有限公司 | [1,2,4] triazol [4,3-a] pyridine derivate, preparation method therefor or medical application thereof |
WO2014186706A1 (en) | 2013-05-17 | 2014-11-20 | Incyte Corporation | Bipyrazole derivatives as jak inhibitors |
WO2014187319A1 (en) | 2013-05-21 | 2014-11-27 | Jiangsu Medolution Ltd | Substituted pyrazolopyrimidines as kinases inhibitors |
WO2014193932A1 (en) | 2013-05-29 | 2014-12-04 | Cephalon, Inc. | Pyrrolotriazines as alk inhibitors |
WO2014202763A1 (en) | 2013-06-20 | 2014-12-24 | Ab Science | Benzimidazole derivatives as selective proteine kinase inhibitors |
WO2014204263A1 (en) | 2013-06-20 | 2014-12-24 | The Asan Foundation | Substituted pyridinone compounds as mek inhibitors |
WO2014210255A1 (en) | 2013-06-26 | 2014-12-31 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
WO2014206343A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
WO2015002894A1 (en) | 2013-07-02 | 2015-01-08 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
WO2015012298A1 (en) | 2013-07-24 | 2015-01-29 | 小野薬品工業株式会社 | Quinoline derivative |
WO2015017533A1 (en) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Ntrk2 fusions |
WO2015017502A1 (en) | 2013-07-31 | 2015-02-05 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
WO2015017610A1 (en) | 2013-07-31 | 2015-02-05 | Gilead Sciences, Inc. | Syk inhibitors |
WO2015017607A2 (en) | 2013-08-02 | 2015-02-05 | Cephalon, Inc. | METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS |
WO2015022926A1 (en) | 2013-08-12 | 2015-02-19 | 大鵬薬品工業株式会社 | Novel fused pyrimidine compound or salt thereof |
WO2015022662A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015031666A1 (en) | 2013-08-28 | 2015-03-05 | Irm Llc | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
WO2015039612A1 (en) | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | Compound inhibiting kinase activities of btk and/or jak3 |
WO2015039334A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015042085A2 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015039333A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015048662A2 (en) | 2013-09-30 | 2015-04-02 | X-Rx Discovery, Inc. | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
WO2015048689A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2015056683A1 (en) | 2013-10-16 | 2015-04-23 | 富士フイルム株式会社 | Nitrogen-containing heterocyclic compound salt or crystal thereof, pharmaceutical composition, and flt3 inhibitor |
WO2015061369A1 (en) | 2013-10-21 | 2015-04-30 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
WO2015061247A2 (en) | 2013-10-21 | 2015-04-30 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
WO2015058589A1 (en) | 2013-10-25 | 2015-04-30 | 上海恒瑞医药有限公司 | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof |
WO2015059668A1 (en) | 2013-10-25 | 2015-04-30 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
WO2015068767A1 (en) | 2013-11-08 | 2015-05-14 | 小野薬品工業株式会社 | Pyrrolo pyrimidine derivative |
WO2015081822A1 (en) | 2013-12-02 | 2015-06-11 | 北京键凯科技有限公司 | 3-furyl-2-cyano-2-acrylamide derivative, preparation method therefor, pharmaceutical composition and use thereof |
WO2015084998A1 (en) | 2013-12-05 | 2015-06-11 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2015089139A1 (en) | 2013-12-10 | 2015-06-18 | Genzyme Corporation | Tropomyosin-related kinase (trk) inhibitors |
WO2015095102A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2015095444A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015095099A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015100217A1 (en) | 2013-12-23 | 2015-07-02 | Gilead Sciences, Inc. | Syk inhibitors |
WO2015100117A1 (en) | 2013-12-26 | 2015-07-02 | Cephalon, Inc. | Pyrazolo[1,5-a]pyridine derivatives and methods of their use |
WO2015116485A1 (en) | 2014-01-29 | 2015-08-06 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as btk inhibitors |
WO2015132799A2 (en) | 2014-02-03 | 2015-09-11 | Cadila Healthcare Limited | Novel heterocyclic compounds |
WO2015119122A1 (en) | 2014-02-04 | 2015-08-13 | アステラス製薬株式会社 | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient |
WO2015127629A1 (en) | 2014-02-27 | 2015-09-03 | Jiangsu Ascentage Biomed Development Inc. | Indoloquinolone compounds as anaplastic lymphoma kinase (alk) inhibitors |
WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
WO2015140054A1 (en) | 2014-03-19 | 2015-09-24 | Boehringer Ingelheim International Gmbh | Heteroaryl syk inhibitors |
WO2015140055A1 (en) | 2014-03-19 | 2015-09-24 | Boehringer Ingelheim International Gmbh | Heteroaryl syk inhibitors |
WO2015140051A1 (en) | 2014-03-19 | 2015-09-24 | Boehringer Ingelheim International Gmbh | Heteroaryl sik inhibitors |
WO2015144614A1 (en) | 2014-03-24 | 2015-10-01 | Ab Science | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors |
WO2015148350A2 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015148354A2 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015148344A2 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | Trka kinase inhibitors, compositions and methods thereof |
WO2015148373A2 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015144801A1 (en) | 2014-03-27 | 2015-10-01 | Janssen Pharmaceutica Nv | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS |
WO2015144799A1 (en) | 2014-03-27 | 2015-10-01 | Janssen Pharmaceutica Nv | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS |
WO2015143692A1 (en) | 2014-03-28 | 2015-10-01 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as axl inhibitors |
WO2015165279A1 (en) | 2014-04-29 | 2015-11-05 | 浙江导明医药科技有限公司 | Polyfluorinated compounds acting as bruton's tyrosine kinase inhibitors |
WO2015169233A1 (en) | 2014-05-07 | 2015-11-12 | 北京赛林泰医药技术有限公司 | Inhibitor of bruton's tyrosine kinase |
WO2015174376A1 (en) | 2014-05-14 | 2015-11-19 | 日産化学工業株式会社 | Tricyclic compound and jak inhibitor |
WO2015175788A1 (en) | 2014-05-15 | 2015-11-19 | Array Biopharma Inc. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
WO2015180685A1 (en) | 2014-05-30 | 2015-12-03 | 北京浦润奥生物科技有限责任公司 | Alk kinase inhibitor, and preparation method and use thereof |
WO2015194764A2 (en) | 2014-06-17 | 2015-12-23 | 한국화학연구원 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
WO2015200341A1 (en) | 2014-06-23 | 2015-12-30 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
WO2016006706A1 (en) | 2014-07-07 | 2016-01-14 | 第一三共株式会社 | Pyridone derivative having tetrahydropyranyl methyl group |
WO2016010809A1 (en) | 2014-07-14 | 2016-01-21 | Gilead Sciences, Inc. | Syk inhibitors |
WO2016019233A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
WO2016021629A1 (en) | 2014-08-06 | 2016-02-11 | 塩野義製薬株式会社 | Heterocyclic and carbocyclic derivative having trka-inhibiting activity |
WO2016027195A1 (en) | 2014-08-21 | 2016-02-25 | Pfizer Inc. | Aminopyrimidinyl compounds as jak inhibitors |
WO2016032209A2 (en) | 2014-08-29 | 2016-03-03 | 양지화학(주) | Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor |
WO2016036796A1 (en) | 2014-09-03 | 2016-03-10 | Genzyme Corporation | Cyclic urea compounds as tropomyosin-related kinase (trk) inhibitors |
WO2016050165A1 (en) | 2014-09-30 | 2016-04-07 | 上海海雁医药科技有限公司 | Azabicyclo derivatives, process for preparation thereof and medical use thereof |
WO2016054483A1 (en) | 2014-10-03 | 2016-04-07 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
WO2016057500A1 (en) | 2014-10-06 | 2016-04-14 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
WO2016054987A1 (en) | 2014-10-11 | 2016-04-14 | 上海翰森生物医药科技有限公司 | Egfr inhibitor, and preparation and application thereof |
WO2016065222A1 (en) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Tricyclic atropisomer compounds |
WO2016066726A2 (en) | 2014-10-30 | 2016-05-06 | Sandoz Ag | Active acrylamides |
WO2016070816A1 (en) | 2014-11-05 | 2016-05-12 | 上海页岩科技有限公司 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof |
WO2016079763A1 (en) | 2014-11-20 | 2016-05-26 | Council Of Scientific & Industrial Research | Novel benzimidazole based egfr inhibitors |
WO2016082713A1 (en) | 2014-11-24 | 2016-06-02 | 中国科学院上海药物研究所 | 2-aminopyrimidine compound and pharmaceutical composition and use thereof |
WO2016091849A2 (en) | 2014-12-11 | 2016-06-16 | Bayer Pharma Aktiengesellschaft | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor |
WO2016097918A1 (en) | 2014-12-18 | 2016-06-23 | Pfizer Inc. | Pyrimidine and triazine derivatives and their use as axl inhibitors |
WO2016104617A1 (en) | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | Quinoline derivative |
WO2016109220A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
WO2016109215A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106652A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Biarylether imidazopyrazine btk inhibitors |
WO2016106626A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
WO2016106624A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106623A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
WO2016106629A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106628A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106627A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016112847A1 (en) | 2015-01-13 | 2016-07-21 | 北京赛特明强医药科技有限公司 | Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof |
WO2016112637A1 (en) | 2015-01-14 | 2016-07-21 | 湖北生物医药产业技术研究院有限公司 | Btk inhibitor |
WO2016116025A1 (en) | 2015-01-20 | 2016-07-28 | 南京明德新药研发股份有限公司 | Jak inhibitor |
WO2016116900A1 (en) | 2015-01-23 | 2016-07-28 | Gvk Biosciences Private Limited | Inhibitors of trka kinase |
WO2016123706A1 (en) | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Novel fluorinated derivatives as egfr inhibitors useful for treating cancers |
WO2016125186A1 (en) | 2015-02-03 | 2016-08-11 | Council Of Scientific & Industrial Research | Novel flavone based egfr inhibitors and process for preparation thereof |
WO2016134320A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2016164286A2 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2016161570A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Azacarbazole btk inhibitors |
WO2016161571A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
WO2016166250A1 (en) | 2015-04-14 | 2016-10-20 | Qurient Co., Ltd | Quinoline derivatives as tam rtk inhibitors |
WO2016173484A1 (en) | 2015-04-29 | 2016-11-03 | 南京明德新药研发股份有限公司 | Jak inhibitors |
WO2016191524A1 (en) | 2015-05-28 | 2016-12-01 | Theravance Biopharma R&D Ip, Llc | Naphthyridine compounds as jak kinase inhibitors |
WO2016192563A1 (en) | 2015-05-29 | 2016-12-08 | 南京明德新药研发股份有限公司 | Janus kinase inhibitor |
WO2016196776A2 (en) | 2015-06-02 | 2016-12-08 | Pharmacyclics Llc. | Inhibitors of bruton's tyrosine kinase |
WO2016196840A1 (en) | 2015-06-03 | 2016-12-08 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2016192074A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2017006953A1 (en) | 2015-07-07 | 2017-01-12 | 塩野義製薬株式会社 | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY |
WO2017006968A1 (en) | 2015-07-07 | 2017-01-12 | 日本たばこ産業株式会社 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
WO2017007987A1 (en) | 2015-07-09 | 2017-01-12 | Merck Patent Gmbh | Pyrimidine derivatives as btk inhibitors and uses thereof |
WO2017011776A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2017008761A1 (en) | 2015-07-16 | 2017-01-19 | 正大天晴药业集团股份有限公司 | Aniline pyrimidine derivatives and uses thereof |
WO2017015363A1 (en) | 2015-07-20 | 2017-01-26 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
WO2017013237A1 (en) * | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
WO2017016463A1 (en) | 2015-07-24 | 2017-02-02 | 上海海雁医药科技有限公司 | Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof |
WO2017026718A1 (en) | 2015-08-07 | 2017-02-16 | 한국과학기술연구원 | Novel 3-(isoxazol-3-yl)-pyrazolo[3,4-d]pyrimidin-4-amine compound, which is ret kinase inhibitor |
WO2017028797A1 (en) | 2015-08-18 | 2017-02-23 | 暨南大学 | Pharmaceutical composition and application replacing quinolone derivative, pharmaceutical acceptable salt, or stereoisomer |
WO2017028816A1 (en) | 2015-08-20 | 2017-02-23 | 浙江海正药业股份有限公司 | Indole derivative, preparation method thereof, and use thereof in pharmaceutical drug |
WO2017043550A1 (en) | 2015-09-08 | 2017-03-16 | 大鵬薬品工業株式会社 | Condensed pyrimidine compound or salt thereof |
WO2017046604A1 (en) | 2015-09-16 | 2017-03-23 | Redx Pharma Plc | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer |
WO2017046302A1 (en) | 2015-09-18 | 2017-03-23 | Ab Science | Novel oxazole derivatives that inhibit syk |
WO2017049992A1 (en) | 2015-09-25 | 2017-03-30 | 浙江博生医药有限公司 | Egfr kinase inhibitor and preparation method and use thereof |
WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
WO2017066014A1 (en) | 2015-10-14 | 2017-04-20 | Sunnylife Pharma Inc. | Bruton's tyrosine kinase inhibitors |
WO2017070708A1 (en) | 2015-10-23 | 2017-04-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
WO2017079205A1 (en) | 2015-11-03 | 2017-05-11 | Theravance Biopharma R&D Ip, Llc | Jak kinase inhibitor compounds for treatment of respiratory disease |
WO2017076355A1 (en) | 2015-11-05 | 2017-05-11 | 湖北生物医药产业技术研究院有限公司 | Pyrimidine derivative and use thereof |
WO2017077507A1 (en) | 2015-11-06 | 2017-05-11 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
WO2017087778A1 (en) | 2015-11-19 | 2017-05-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
WO2017091544A1 (en) | 2015-11-24 | 2017-06-01 | Theravance Biopharma R&D Ip, Llc | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
WO2017097224A1 (en) | 2015-12-11 | 2017-06-15 | 四川科伦博泰生物医药股份有限公司 | Azetidine derivative, preparation method therefor, and use thereof |
WO2017106429A2 (en) | 2015-12-16 | 2017-06-22 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as btk inhibitors |
WO2017114383A1 (en) | 2015-12-31 | 2017-07-06 | 合肥中科普瑞昇生物医药科技有限公司 | Novel kinase inhibitor against wild-type egfr and mutated egfr |
WO2017117680A1 (en) | 2016-01-06 | 2017-07-13 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as egfr inhibitors |
WO2017121444A1 (en) | 2016-01-11 | 2017-07-20 | Merck Patent Gmbh | Quinolin-2-one derivatives |
WO2017123695A1 (en) | 2016-01-13 | 2017-07-20 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
WO2017127371A1 (en) | 2016-01-21 | 2017-07-27 | Sunnylife Pharma Inc. | Bruton's tyrosine kinase inhibitors |
WO2017129116A1 (en) | 2016-01-26 | 2017-08-03 | 杭州华东医药集团新药研究院有限公司 | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof |
WO2017128917A1 (en) | 2016-01-29 | 2017-08-03 | 北京诺诚健华医药科技有限公司 | Parazole condensed-ring derivatives and preparation method thereof and application thereof in treatment of cancers, inflammation and immune diseases |
WO2017135399A1 (en) | 2016-02-04 | 2017-08-10 | 塩野義製薬株式会社 | Nitrogen-containing heterocycle having trka inhibitory activity, and carbocyclic derivative |
WO2017140254A1 (en) | 2016-02-19 | 2017-08-24 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof |
WO2017146116A1 (en) | 2016-02-23 | 2017-08-31 | 大鵬薬品工業株式会社 | Novel condensed pyrimidine compound or salt thereof |
WO2017148440A1 (en) | 2016-03-04 | 2017-09-08 | 华东理工大学 | Pteridinone derivative serving as flt3 inhibitor, and uses |
WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
WO2017167182A1 (en) | 2016-04-01 | 2017-10-05 | 合肥中科普瑞昇生物医药科技有限公司 | Selective c-kit kinase inhibitor |
WO2017190048A1 (en) | 2016-04-29 | 2017-11-02 | X-Chem, Inc. | Covalent btk inhibitors and uses thereof |
WO2017205459A1 (en) | 2016-05-26 | 2017-11-30 | Kalyra Pharmaceuticals, Inc. | Egfr inhibitor compounds |
WO2017215630A1 (en) | 2016-06-16 | 2017-12-21 | 正大天晴药业集团股份有限公司 | Pyrrolopyrimidine crystal for preparing jak inhibitor |
WO2018001251A1 (en) | 2016-06-27 | 2018-01-04 | 杭州雷索药业有限公司 | Benzofuran pyrazole amine protein kinase inhibitor |
WO2018001331A1 (en) | 2016-06-30 | 2018-01-04 | 杭州华东医药集团新药研究院有限公司 | Imidazopyridinamine phenyl derivative and use thereof |
WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
WO2018009017A1 (en) | 2016-07-07 | 2018-01-11 | Daewoong Pharmaceutical Co., Ltd. | NOVEL 4-AMINOPYRAZOLO[3,4-d]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
WO2018010514A1 (en) | 2016-07-13 | 2018-01-18 | 南京天印健华医药科技有限公司 | Heterocyclic compound used as fgfr inhibitor |
WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
WO2018028438A1 (en) | 2016-08-09 | 2018-02-15 | 南京天印健华医药科技有限公司 | Heterocyclic compound as fgfr inhibitor |
WO2018035080A1 (en) | 2016-08-16 | 2018-02-22 | Merck Patent Gmbh | 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof |
WO2018044767A2 (en) | 2016-08-29 | 2018-03-08 | The Regents Of The University Of Michigan | Aminopyrimidines as alk inhibitors |
WO2018053190A1 (en) | 2016-09-14 | 2018-03-22 | Gilead Sciences, Inc. | Syk inhibitors |
WO2018053189A2 (en) | 2016-09-14 | 2018-03-22 | Gilead Sciences, Inc. | Syk inhibitors |
WO2018049781A1 (en) | 2016-09-19 | 2018-03-22 | 北京天诚医药科技有限公司 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof |
WO2018050052A1 (en) | 2016-09-19 | 2018-03-22 | 郑州泰基鸿诺医药股份有限公司 | Compound containing pyrimidine ring, egfr inhibitor and application thereof |
WO2018060714A1 (en) | 2016-09-29 | 2018-04-05 | Daiichi Sankyo Company, Limited | Pyridine compound |
WO2018071454A1 (en) | 2016-10-10 | 2018-04-19 | Andrews Steven W | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2018071447A1 (en) | 2016-10-10 | 2018-04-19 | Andrews Steven W | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2018079759A1 (en) | 2016-10-31 | 2018-05-03 | 塩野義製薬株式会社 | Fused heterocycle having trka inhibitory activity and fused carbocycle derivative |
WO2018088780A1 (en) | 2016-11-08 | 2018-05-17 | Daewoong Pharmaceutical Co., Ltd. | Novel pyrrolopyrimidine derivatives and pharmaceutical composition comprising the same |
WO2018090792A1 (en) | 2016-11-15 | 2018-05-24 | 杭州和正医药有限公司 | Selective bruton's tyrosine kinase inhibitor and use thereof |
WO2018094134A1 (en) | 2016-11-18 | 2018-05-24 | The Regents Of The University Of Michigan | 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-ones as alk inhibitors |
WO2018095398A1 (en) | 2016-11-24 | 2018-05-31 | 中国科学院上海药物研究所 | Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method and use thereof |
WO2018108083A1 (en) | 2016-12-12 | 2018-06-21 | 杭州英创医药科技有限公司 | Heterocyclic compound as syk inhibitor and/or syk-hdac dual inhibitor |
WO2018108064A1 (en) | 2016-12-13 | 2018-06-21 | 南京明德新药研发股份有限公司 | Spiro-aryl-phosphorus-oxygen compound as fourth generation of egfr kinase inhibitor |
WO2018112140A1 (en) | 2016-12-15 | 2018-06-21 | Ariad Pharmaceuticals, Inc. | Benzimidazole compounds as c-kit inhibitors |
WO2018112136A1 (en) | 2016-12-15 | 2018-06-21 | Ariad Pharmaceuticals, Inc. | Aminothiazole compounds as c-kit inhibitors |
WO2018121228A1 (en) | 2016-12-28 | 2018-07-05 | 中国科学院上海药物研究所 | Compound having axl inhibitory activity, preparation method therefor and use thereof |
WO2018121650A1 (en) | 2016-12-29 | 2018-07-05 | 南京明德新药研发股份有限公司 | Fgfr inhibitor |
WO2018121758A1 (en) | 2016-12-30 | 2018-07-05 | 南京明德新药研发股份有限公司 | Quinazoline compound for egfr inhibition |
WO2018127184A1 (en) | 2017-01-06 | 2018-07-12 | 北京赛林泰医药技术有限公司 | Anaplastic lymphoma kinase inhibitor and preparation method and use thereof |
WO2018129645A1 (en) | 2017-01-10 | 2018-07-19 | Wang, Wei | Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
WO2018133151A1 (en) | 2017-01-20 | 2018-07-26 | 成都倍特药业有限公司 | Compound used as bruton's tyrosine kinase inhibitor and preparation method and application thereof |
WO2018145525A1 (en) | 2017-02-08 | 2018-08-16 | 中国医药研究开发中心有限公司 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof |
WO2018153293A1 (en) | 2017-02-27 | 2018-08-30 | 北京赛特明强医药科技有限公司 | Dioxanoquinazoline, dioxanoquinazoline-type compound, preparation method therefor and use thereof |
WO2018153373A1 (en) | 2017-02-27 | 2018-08-30 | 贝达药业股份有限公司 | Fgfr inhibitor and application thereof |
WO2018154131A1 (en) | 2017-02-27 | 2018-08-30 | Merck Patent Gmbh | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone |
WO2018170381A1 (en) | 2017-03-16 | 2018-09-20 | Andrews Steven W | Macrocyclic compounds as ros1 kinase inhibitors |
WO2018175512A1 (en) | 2017-03-22 | 2018-09-27 | Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. | Bruton's tyrosine kinase inhibitors |
WO2018187355A1 (en) | 2017-04-03 | 2018-10-11 | Health Research Inc. | Met kinase inhibitors and uses therefor |
WO2018192532A1 (en) | 2017-04-19 | 2018-10-25 | 华东理工大学 | Heterocyclic compound as btk inhibitor and application thereof |
WO2018192536A1 (en) | 2017-04-19 | 2018-10-25 | 华东理工大学 | Pyrimido-heterocyclic compound serving as bruton tyrosine kinase inhibitor and applications thereof |
WO2018196757A1 (en) | 2017-04-25 | 2018-11-01 | 中国药科大学 | 4-aminopyrimidine compound, and preparation method therefor and application thereof |
WO2018199166A1 (en) | 2017-04-27 | 2018-11-01 | 持田製薬株式会社 | Novel tetrahydronaphthyl urea derivatives |
WO2018204238A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Fused imidazo-piperidine jak inhibitor compound |
WO2018208132A1 (en) | 2017-05-12 | 2018-11-15 | Korea Research Institute Of Chemical Technology | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient |
WO2018215389A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
WO2018215390A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
WO2018218963A1 (en) | 2017-06-02 | 2018-12-06 | 无锡双良生物科技有限公司 | Pharmaceutically acceptable salt of egfr inhibitor, crystal form thereof, preparation method therefor and application thereof |
WO2018228475A1 (en) | 2017-06-14 | 2018-12-20 | 正大天晴药业集团股份有限公司 | Syk inhibitor and use method therefor |
WO2018233655A1 (en) | 2017-06-22 | 2018-12-27 | 上海度德医药科技有限公司 | Heteroaryl compound having pharmaceutical activity |
WO2019001419A1 (en) | 2017-06-27 | 2019-01-03 | Janssen Pharmaceutica Nv | New quinolinone compounds |
WO2019010295A1 (en) | 2017-07-05 | 2019-01-10 | Cs Pharmatech Limited | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY |
WO2019034076A1 (en) | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr inhibitor and medical application thereof |
WO2019034075A1 (en) | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr and egfr inhibitor |
WO2019034538A1 (en) | 2017-08-18 | 2019-02-21 | Universität Regensburg | Synthesis, pharmacology and use of new and selective fms-like tyrosine kinase 3 (flt3) flt3 inhibitors |
WO2019034128A1 (en) | 2017-08-18 | 2019-02-21 | 浙江海正药业股份有限公司 | Pyrrolotriazine derivative, preparation method and use thereof |
WO2019034153A1 (en) | 2017-08-18 | 2019-02-21 | 北京韩美药品有限公司 | Chemical compound, pharmaceutical composition thereof, and use and application thereof |
Non-Patent Citations (92)
Title |
---|
; CHENG ET AL., EUR J MED CHEM., vol. 126, 27 January 2017 (2017-01-27), pages 476 - 490 |
ABBASPOUR BABAEI ET AL., DRUG DES DEVEL THER., vol. 10, 1 August 2016 (2016-08-01), pages 2443 - 59 |
ANDRICKGANDHI, ANN PHARMACOTHER., vol. 51, no. 12, December 2017 (2017-12-01), pages 1090 - 1098 |
AWBROWN, DRUGS AGING., vol. 34, no. 7, July 2017 (2017-07-01), pages 509 - 527 |
BAHRAMI ET AL., J CELL PHYSIOL., vol. 232, no. 10, October 2017 (2017-10-01), pages 2657 - 2673 |
BARTAULA-BREVIK ET AL., EXPERT OPIN INVESTIG DRUGS, vol. 27, no. 4, April 2018 (2018-04-01), pages 377 - 387 |
BEARDSLEE, J ADV PRACT ONCOL., vol. 9, no. 1, January 2018 (2018-01-01), pages 94 - 101 |
BHANGOOSIGAL, CURR ONCOL REP., vol. 21, no. 2, 4 February 2019 (2019-02-04), pages 14 |
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1421373-98-9 |
CHEN, CURR TOP MED CHEM., vol. 17, no. 28, 20 November 2017 (2017-11-20), pages 3099 - 3130 |
CHEN, CURRTOP MED CHEM., vol. 17, no. 28, 20 November 2017 (2017-11-20), pages 3099 - 3130 |
CHENCHEN, DRUG DES DEVEL THER., vol. 9, 9 February 2015 (2015-02-09), pages 773 - 9 |
CHENG ET AL., CURR MED CHEM., vol. 23, no. 29, 2016, pages 3343 - 3359 |
COCCO ET AL., NAT REV CLIN ONCOL., vol. 15, no. 12, December 2018 (2018-12-01), pages 731 - 747 |
CRESCENZO, CURR OPIN PHARMACOL., vol. 23, August 2015 (2015-08-01), pages 39 - 44 |
ELSHOURY ET AL., EXPERT REV ANTICANCER THER., vol. 19, no. 3, March 2019 (2019-03-01), pages 273 - 286 |
EROGLU ET AL., THER ADV MED ONCOL., vol. 8, no. 1, January 2016 (2016-01-01), pages 48 - 56 |
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 12, no. 12, December 2002 (2002-12-01), pages 1903 - 1907 |
FACCHINETTI ET AL., CANCER TREAT REV., vol. 55, April 2017 (2017-04-01), pages 83 - 95 |
FUJIMURA ET AL., EXPERT OPIN INVESTIG DRUGS, vol. 28, no. 2, February 2019 (2019-02-01), pages 143 - 148 |
GALLOGLYLAZARUS, J BLOOD MED., vol. 7, 19 April 2016 (2016-04-19), pages 73 - 83 |
GARNETTMARAIS, CANCER CELL, vol. 6, no. 4, 2004, pages 313 - 319 |
GEAHLEN, TRENDS PHARMACOL SCI., vol. 35, no. 8, August 2014 (2014-08-01), pages 414 - 22 |
GOIDZIK-SPYCHALSKA ET AL., CURR TREAT OPTIONS ONCOL., vol. 15, no. 4, December 2014 (2014-12-01), pages 670 - 82 |
GOLDINGS ET AL., MOL CANCER., vol. 17, no. 1, 19 February 2018 (2018-02-19), pages 52 |
GOLDSTEIN ET AL., ANN. REV. CELL BIOL., vol. 1, 1985, pages 1 - 39 |
GULER ET AL., CAN CELL, vol. 32, 2017, pages 221 - 237 |
HATA ET AL., NAT MED, vol. 22, no. 3, 2016, pages 262 - 269 |
HATA ET AL., NAT. MED., 2016 |
HE, EXPERT OPIN THER PAT., vol. 29, no. 2, February 2019 (2019-02-01), pages 137 - 149 |
HOBBS ET AL., HEMATOL ONCOL CLIN NORTH AM., vol. 31, no. 4, August 2017 (2017-08-01), pages 613 - 626 |
JIN ET AL., PATHOL ONCOL RES., 31 January 2019 (2019-01-31) |
KAKADIA, ONCO TARGETS THER., vol. 11, 17 October 2018 (2018-10-17), pages 7095 - 7107 |
KANE, EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 16, no. 2, February 2006 (2006-02-01), pages 147 - 164 |
KARACHALIOU, EXPERT OPIN INVESTIG DRUGS, vol. 26, no. 6, June 2017 (2017-06-01), pages 713 - 722 |
KATOH, INT J MOL MED., vol. 38, no. l, July 2016 (2016-07-01), pages 3 - 15 |
KHALIQUEBANERJEE, EXPERT OPIN INVESTIG DRUGS., vol. 26, no. 9, September 2017 (2017-09-01), pages 1073 - 1081 |
KIM HO, ARCH PHARM RES., vol. 42, no. 2, February 2019 (2019-02-01), pages 171 - 181 |
LANGELO, CANCERS, vol. 10, no. 4, 4 April 2018 (2018-04-04) |
LEAMONLOWE, PROC NATL ACAD SCI USA., vol. 88, 1991, pages 5572 - 5576 |
LEROYCONSTANTINESCU, LEUKEMIA, vol. 31, no. 5, May 2017 (2017-05-01), pages 1023 - 1038 |
LIANGET, EUR J MED CHEM., vol. 151, 10 May 2018 (2018-05-10), pages 315 - 326 |
LINSHAW, J THORAC ONCOL., vol. 12, no. 11, November 2017 (2017-11-01), pages 1611 - 1625 |
LIU ET AL., THER CLIN RISK MANAG., vol. 14, 20 July 2018 (2018-07-20), pages 1247 - 1252 |
LIU, CURR MED CHEM., vol. 24, no. 6, 2017, pages 590 - 613 |
LIUMAMORSKA-DYGA, J HEMATOL ONCOL., vol. 10, 2017, pages 145 |
MARIE DUTREIX: "Abstract 1110: AsiDNA induce tumor sensitivity to PARP inhibitors in homologous recombination proficient breast cancer AsiDNA induce tumor sensitivity to PARP inhibitors in homologous recombination proficient breast cancer | Cancer Research", AACR ANNUAL MEETING 2017; APRIL 1-5, 2017; WASHINGTON, DC, 1 July 2017 (2017-07-01), pages 1 - 5, XP055491302 * |
MICHELLYS, BIOORG MED CHEM LETT., vol. 26, no. 3, 1 February 2016 (2016-02-01), pages 1090 - 1096 |
MILIK ET AL., EUR J MED CHEM., vol. 142, 15 December 2017 (2017-12-15), pages 131 - 151 |
MIYAMOTO ET AL., JPN J CLIN ONCOL., vol. 48, no. 6, 1 June 2018 (2018-06-01), pages 503 - 513 |
MOUNTZIOS, ANN TRANSL MED., vol. 6, no. 8, April 2018 (2018-04-01), pages 140 |
MURTUZA ET AL., CANCER RES., vol. 79, no. 4, 15 February 2019 (2019-02-15), pages 689 - 698 |
MYERS, J MED CHEM., vol. 59, no. 8, 28 April 2016 (2016-04-28), pages 3593 - 608 |
NORMAN, EXPERT OPIN THER PAT., vol. 24, no. 5, May 2014 (2014-05-01), pages 573 - 95 |
PACENTA ET AL., DRUG DES DEVEL THER., vol. 12, 23 October 2018 (2018-10-23), pages 3549 - 3561 |
PETERS, CURR TREAT OPTIONS ONCOL., vol. 19, no. 7, 28 May 2018 (2018-05-28), pages 37 |
PITOIAJERKOVICH, DRUG DES DEVEL THER., vol. 10, 11 March 2016 (2016-03-11), pages 1119 - 31 |
PORTA ET AL., CRIT REV ONCOL HEMATOL., vol. 113, May 2017 (2017-05-01), pages 256 - 267 |
QI ET AL., WORLD J GASTROENTEROL., vol. 21, no. 18, 14 May 2015 (2015-05-14), pages 5445 - 53 |
QU, ONCOTARGET, vol. 8, no. 17, 25 April 2017 (2017-04-25), pages 29501 - 29518 |
RAMIREZ ET AL., NAT COMM, 2016 |
RIZVIBORAD, J GASTROINTEST ONCOL., vol. 7, no. 5, October 2016 (2016-10-01), pages 789 - 796 |
ROLFO ET AL., EXPERT OPIN INVESTIG DRUGS, vol. 24, no. 11, 2015, pages 1493 - 500 |
ROLFO, EXPERT OPIN INVESTIG DRUGS., vol. 24, no. 11, 2015, pages 1493 - 500 |
ROSKOSKI, PHARMACOL RES., vol. 129, March 2018 (2018-03-01), pages 65 - 83 |
ROSKOSKI, PHARMACOL RES., vol. 135, September 2018 (2018-09-01), pages 239 - 258 |
ROSKOSKI, PHARMACOL RES., vol. 139, January 2019 (2019-01-01), pages 395 - 411 |
ROSKOSKISADEGHI-NEJAD, PHARMACOL RES., vol. 128, February 2018 (2018-02-01), pages 1 - 17 |
SARKISIANDAVAR, DRUG DES DEVEL THER., vol. 12, 20 August 2018 (2018-08-20), pages 2553 - 2565 |
SENKEVITCH, DURUM, CYTOKINE., vol. 98, October 2017 (2017-10-01), pages 33 - 41 |
SGAMBATO, EXPERT REV ANTICANCER THER., vol. 18, no. 1, January 2018 (2018-01-01), pages 71 - 80 |
SHARMA ET AL., CELL, vol. 141, 2010, pages 69 - 80 |
SHEN ET AL., J HEMATOL ONCOL., vol. 11, no. 1, 19 September 2018 (2018-09-19), pages 120 |
SHORT ET AL., THER ADV HEMATOL., vol. 10, 15 February 2019 (2019-02-15) |
SINGH ET AL., MINI REV MED CHEM., vol. 16, no. 14, 2016, pages 1134 - 66 |
SPAGNUOLO ET AL., EXPERT OPIN EMERG DRUGS., vol. 23, no. 3, September 2018 (2018-09-01), pages 231 - 241 |
STEEB ET AL., EUR J CANCER., vol. 103, November 2018 (2018-11-01), pages 41 - 51 |
STONE, BEST PRACT RES CLIN HAEMATOL., vol. 31, no. 4, December 2018 (2018-12-01), pages 401 - 404 |
STRAUGHAN, CURR DRUG TARGETS, vol. 17, no. 6, 2016, pages 739 - 45 |
TAN ET AL., ONCO TARGETS THER., vol. 12, 18 January 2019 (2019-01-18), pages 635 - 645 |
TIONG ISWEI AH, GENES CHROMOSOMES CANCER, 12 March 2019 (2019-03-12) |
TRAXLER, EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 8, no. 12, December 1998 (1998-12-01), pages 1599 - 1625 |
TROJANIELLO, EXPERT REV CLIN PHARMACOL., vol. 12, no. 3, March 2019 (2019-03-01), pages 173 - 178 |
TSAI ET AL., PNAS, vol. 105, no. 8, 26 February 2008 (2008-02-26), pages 3041 - 3046 |
WILMOTT ET AL., CANCER THERAPY: CLINICAL, vol. 18, no. 5, 2012 |
WU ET AL., J HEMATOL ONCOL., vol. 11, no. 1, 4 December 2018 (2018-12-04), pages 133 |
WU ET AL., J HEMATOL ONCOL., vol. 9, no. 1, 2 September 2016 (2016-09-02), pages 80 |
WU ET AL., ONCOTARGET., vol. 8, no. 4, 24 January 2017 (2017-01-24), pages 7201 - 7207 |
ZHANG ET AL., EUR J MED CHEM., vol. 108, 27 January 2016 (2016-01-27), pages 495 - 504 |
ZHANG, EXPERT OPIN THER PAT., vol. 29, no. 1, January 2019 (2019-01-01), pages 25 - 41 |
ZHI ET AL., EUR J MED CHEM., vol. 155, 15 July 2018 (2018-07-15), pages 303 - 315 |
ZSCHABITZGRULLICH, RECENT RESULTS CANCER RES., vol. 211, 2018, pages 187 - 198 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
KR20220165628A (en) * | 2021-06-08 | 2022-12-15 | 한국과학기술원 | Composition for treating or preventing colorectal cancer in combination, comprising SYK inhibitor |
KR102657354B1 (en) | 2021-06-08 | 2024-04-15 | 한국과학기술원 | Composition for treating or preventing colorectal cancer in combination, comprising SYK inhibitor |
Also Published As
Publication number | Publication date |
---|---|
IL284856A (en) | 2021-08-31 |
CA3129665A1 (en) | 2020-09-24 |
BR112021018168A2 (en) | 2021-11-16 |
EA202192575A1 (en) | 2022-01-14 |
CN114364798A (en) | 2022-04-15 |
BR112021018168B1 (en) | 2023-11-28 |
EP3942045A1 (en) | 2022-01-26 |
US20220143049A1 (en) | 2022-05-12 |
JP2022526713A (en) | 2022-05-26 |
KR20210142154A (en) | 2021-11-24 |
AU2020242287A1 (en) | 2021-09-02 |
MX2021009863A (en) | 2021-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220143049A1 (en) | A dbait molecule in combination with kinase inhibitor for the treatment of cancer | |
US20210023116A1 (en) | Treatment of cancer by systemic administration of dbait molecules | |
CA2802463C (en) | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates | |
US11504374B2 (en) | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder | |
US20200407720A1 (en) | A dbait molecule against acquired resistance in the treatment of cancer | |
WO2021148581A1 (en) | Novel dbait molecule and its use | |
CA3159348A1 (en) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors | |
US20230235327A1 (en) | A dbait molecule in combination with kras inhibitor for the treatment of cancer | |
EA045717B1 (en) | DBAIT COMPOUNDS IN COMBINATION WITH KINASE INHIBITORS FOR THE TREATMENT OF CANCER | |
AU2015202211B2 (en) | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20710972 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3129665 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020242287 Country of ref document: AU Date of ref document: 20200319 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021553852 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021018168 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217033652 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020710972 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2020710972 Country of ref document: EP Effective date: 20211021 |
|
ENP | Entry into the national phase |
Ref document number: 112021018168 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210913 |